Revvity (RVTY) 10-Q 7 Aug 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jul. 01, 2018	Aug. 02, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	PERKINELMER INC
Entity Central Index Key	31,791
Current Fiscal Year End Date	--07-01
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Jul. 1, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		110,734,011
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes

Condensed Consolidated Income S

Condensed Consolidated Income Statements - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Revenue from Contract with Customer, Excluding Assessed Tax	$ 703,362	$ 546,962	$ 1,347,334	$ 1,061,077
Cost of Revenue	363,222	289,360	714,972	563,719
Selling, general and administrative expenses	204,880	149,859	404,605	296,867
Research and development expenses	47,196	33,560	93,180	66,846
Restructuring and contract termination charges, net	0	0	6,578	9,651
Operating income from continuing operations	88,064	74,183	127,999	123,994
Interest and other expense, net	16,356	3,391	27,786	13,219
Income from continuing operations before income taxes	71,708	70,792	100,213	110,775
Provision for income taxes	7,035	8,066	9,505	11,987
Income from continuing operations	64,673	62,726	90,708	98,788
(Loss) income from discontinued operations before income taxes	0	(3,109)	0	650
(Loss) gain on disposition of discontinued operations before income taxes	(551)	180,377	(551)	180,377
Provision for income taxes on discontinued operations and dispositions	59	35,925	70	37,143
(Loss) income from discontinued operations and dispositions	(610)	141,343	(621)	143,884
Net income	$ 64,063	$ 204,069	$ 90,087	$ 242,672
Basic earnings (loss) per share:
Income (loss) from continuing operations (per share)	$ 0.59	$ 0.57	$ 0.82	$ 0.90
Gain (loss) on discontinued operations and dispositions (per share)	(0.01)	1.29	(0.01)	1.31
Net income (per share)	0.58	1.86	0.82	2.21
Diluted earnings (loss) per share:
Income (loss) from continuing operations (per share)	0.58	0.57	0.81	0.89
Gain (loss) on discontinued operations and dispositions (per share)	(0.01)	1.28	(0.01)	1.30
Net income (per share)	$ 0.57	$ 1.84	$ 0.81	$ 2.20
Weighted average shares of common stock outstanding:
Basic (in shares)	110,477	109,894	110,386	109,681
Diluted (in shares)	111,452	110,762	111,391	110,484
Cash dividends per common share	$ 0.07	$ 0.07	$ 0.14	$ 0.14
Product [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 495,608	$ 355,001	$ 943,216	$ 688,715
Cost of Goods and Services Sold	(229,723)	(173,040)	(449,979)	(336,064)
Service [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	207,754	191,961	404,118	372,362
Cost of Goods and Services Sold	$ (133,499)	$ (116,320)	$ (264,993)	$ (227,655)

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Net income	$ 64,063	$ 204,069	$ 90,087	$ 242,672
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Foreign currency translation adjustments	(102,592)	18,192	(84,093)	37,400
Unrealized gains on securities, net of tax	4	11	45	34
Other comprehensive (loss) income	(102,588)	18,203	(84,048)	37,434
Comprehensive (loss) income	$ (38,525)	$ 222,272	$ 6,039	$ 280,106

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jul. 01, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 163,392	$ 202,134
Accounts receivable, net	564,041	552,304
Inventories	366,961	351,675
Other current assets	108,019	93,842
Total current assets	1,202,413	1,199,955
Property, plant and equipment, net:
At cost	706,566	630,919
Accumulated depreciation	(402,028)	(332,853)
Property, plant and equipment, net	304,538	298,066
Intangible assets, net	1,270,867	1,346,940
Goodwill	2,940,825	3,002,198
Other assets, net	239,135	244,304
Total assets	5,957,778	6,091,463
Current liabilities:
Current portion of long-term debt	17,315	217,306
Accounts payable	197,128	222,093
Accrued expenses and other current liabilities	7,443	8,759
Accrued expenses and other current liabilities	488,642	500,642
Current liabilities of discontinued operations	2,165	2,102
Total current liabilities	712,693	950,902
Long-term debt	1,983,953	1,788,803
Long-term liabilities	743,955	848,570
Total liabilities	3,440,601	3,588,275
Commitments and contingencies (see Note 20)
Stockholders' equity:
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	0	0
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 110,716,000 shares and 110,361,000 shares at July 1, 2018 and at December 31, 2017, respectively	110,716	110,361
Capital in excess of par value	73,740	58,828
Retained earnings	2,463,287	2,380,517
Accumulated other comprehensive loss	(130,566)	(46,518)
Total stockholders’ equity	2,517,177	2,503,188
Total liabilities and stockholders’ equity	$ 5,957,778	$ 6,091,463

Condensed Consolidated Balance5

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jul. 01, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 1	$ 1
Preferred stock, authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 1	$ 1
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	110,716,000	110,361,000
Common stock, outstanding	110,716,000	110,361,000

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017
Operating activities:
Net income	$ 90,087	$ 242,672
Loss (income) from discontinued operations and dispositions, net of income taxes	621	(143,884)
Income from continuing operations	90,708	98,788
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:
Restructuring and contract termination charges, net	6,578	9,651
Depreciation and amortization	88,225	49,505
Gain on disposition of businesses and assets, net	0	301
Stock-based compensation	12,148	11,767
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	7,065	909
Amortization of deferred debt financing costs and accretion of discount	1,519	1,231
Amortization of acquired inventory revaluation	18,160	4,240
Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:
Accounts receivable, net	(18,768)	5,215
Inventories	(42,993)	(9,913)
Accounts payable	(24,384)	(20,855)
Accrued expenses and other	(79,831)	(55,193)
Net cash provided by operating activities of continuing operations	58,427	95,646
Net cash provided by operating activities of discontinued operations	0	6,207
Net cash provided by operating activities	58,427	101,853
Investing activities:
Capital expenditures	(39,608)	(11,473)
Proceeds from surrender of life insurance policies	72	45
Proceeds from Divestiture of Businesses	173	0
Activity related to acquisitions and investments, net of cash and cash equivalents acquired	(40,557)	(123,578)
Net cash used in investing activities of continuing operations	(79,920)	(135,006)
Net cash provided by investing activities of discontinued operations	0	276,982
Net cash (used in) provided by investing activities	(79,920)	141,976
Financing activities:
Payments on borrowings	(667,000)	(145,950)
Proceeds from borrowings	342,000	146,952
Proceeds from sale of senior debt	369,340	0
Payments of debt financing costs	(2,634)	0
Settlement of cash flow hedges	(32,711)	(4,314)
Net payments on other credit facilities	(10,154)	(577)
Payments for acquisition-related contingent consideration	0	(8,940)
Proceeds from issuance of common stock under stock plans	8,348	13,223
Purchases of common stock	(4,649)	(3,265)
Dividends paid	(15,471)	(15,363)
Net Cash Provided by (Used in) Financing Activities, Continuing Operations	(12,931)	(18,234)
Cash Provided by (Used in) Financing Activities, Discontinued Operations	0	(533)
Net cash used in financing activities	(12,931)	(18,767)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	(4,351)	14,928
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalent	(38,775)	239,990
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at beginning of period	202,371	376,568
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at end of period	163,596	616,558
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 202,371	$ 376,568

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jul. 01, 2018
Accounting Policies [Abstract]
Basis of Accounting [Text Block]	Basis of Presentation The condensed consolidated financial statements included herein have been prepared by PerkinElmer, Inc. (the “Company”), in accordance with accounting principles generally accepted in the United States of America (the “U.S.” or the "United States") and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information in the footnote disclosures of the financial statements has been condensed or omitted where it substantially duplicates information provided in the Company’s latest audited consolidated financial statements, in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2017 , filed with the SEC (the “ 2017 Form 10-K”). The balance sheet amounts at December 31, 2017 in this report were derived from the Company’s audited 2017 consolidated financial statements included in the 2017 Form 10-K. The condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods indicated. The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts and classifications of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three and six months ended July 1, 2018 and July 2, 2017 , respectively, are not necessarily indicative of the results for the entire fiscal year or any future period. The Company’s fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. The fiscal year ending December 30, 2018 (" fiscal year 2018 ") will include 52 weeks, and the fiscal year ended December 31, 2017 (" fiscal year 2017 ") included 52 weeks. Recently Adopted and Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In June 2018, the FASB issued Accounting Standards Update No. 2018-07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting ("ASU 2018-07") which supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-employees , and expands the scope of Topic 718 (which currently only includes share-based payments to employees) to also include share-based payments issued to non-employees for goods and services, except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards, except for financing transactions, or awards issued to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers ("Topic 606"). The provisions of this guidance are to be applied using a modified retrospective approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified non-employee awards that have not been settled as of the adoption date and (2) equity-classified non-employee awards for which a measurement date has not been established. ASU 2018-07 is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606. The Company early adopted the provisions of this guidance effective July 2, 2018. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flow. In March 2018, the FASB Issued Accounting Standards Update No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("ASU 2018-05"). ASU 2018-05 was issued to incorporate into Topic 740 recent SEC guidance related to the income tax accounting implications of the Tax Cut and Jobs Act (the "Tax Act"). The SEC issued Staff Accounting Bulletin No. 118 ("SAB 118") to address concerns about reporting entities’ ability to timely comply with the accounting requirements to recognize all of the effects of the Tax Act in the period of enactment. SAB 118 permits companies to disclose that some or all of the income tax effects from the Tax Act are incomplete by the due date of the financial statements, and if possible, disclose a reasonable estimate of such tax effects. ASU 2018-05 is effective immediately. The Company is applying the guidance in ASU 2018-05 when accounting for the enactment date effects of the Tax Act. At July 1, 2018, the Company has not completed the accounting for all of the tax effects of the Tax Act; however, it has made a reasonable estimate of their effects based on currently available information. Management will continue to refine the calculations as additional guidance is available. These estimates may be affected as additional clarification and implementation guidance becomes available. These changes could be material to income tax expense (see Note 9, Income Taxes for further disclosures). In February 2018, the FASB Issued Accounting Standards Update No. 2018-03, Technical Corrections and Improvements to Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2018-03") . ASU 2018-03 was issued to clarify certain aspects of guidance concerning the recognition of financial assets and liabilities established in Accounting Standards Update No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"). This includes treatment for discontinuations and adjustments for equity securities without a readily determinable market value, forward contracts and purchased options, presentation requirements for certain fair value option liabilities, fair value option liabilities denominated in a foreign currency, and transition guidance for equity securities without a readily determinable fair value. ASU 2018-03 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years beginning after June 15, 2018. Early adoption is permitted for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, as long as the Company has adopted ASU 2016-01. The Company is evaluating the requirements of this guidance. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In February 2018, the FASB Issued Accounting Standards Update No. 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income ("ASU 2018-02") . ASU 2018-02 provides entities with an option to reclassify stranded tax effects within Accumulated Other Comprehensive Income ("AOCI") to retained earnings in each period in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Act (or portion thereof) is recorded. ASU 2018-02 requires entities to disclose a description of the accounting policy for releasing income tax effects from AOCI; whether they elect to reclassify the stranded income tax effects from the Tax Act; and information about the other income tax effects that are reclassified. ASU 2018-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, and entities should apply the proposed amendments either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Act is recognized. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In August 2017, the FASB issued Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815), Targeted Improvements to Accounting for Hedging Activities ("ASU 2017-12") , which amends the hedge accounting recognition and presentation requirements in Topic 815. ASU 2017-12 makes targeted changes to the existing hedge accounting model to better align an entity’s financial reporting for hedging relationships with the entity’s risk management activities, and to reduce the complexity of, and simplify the application of, the hedge accounting model. Specifically, ASU 2017-12 expands the types of transactions eligible for hedge accounting, eliminates the requirement to separately measure and present hedge ineffectiveness, simplifies the way assessments of hedge ineffectiveness may be performed, relaxes the documentation requirements for entering into hedging positions, provides targeted improvements to fair value hedges of interest rate risk, and permits an entity to exclude the change in the fair value of cross-currency basis spreads in currency swaps from the assessment of hedge effectiveness. The standard also requires entities to provide new disclosures about the impact fair value and cash flow hedges have on their income statements and about cumulative basis adjustments arising from fair value hedges. The provisions of this guidance are to be applied using a modified retrospective approach to existing hedging relationships as of the adoption date. However, the transition provisions allow for certain elections at the date of adoption and entities may choose to apply any of the provided elections. ASU 2017-12 is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted, including adoption in any interim period. The Company early adopted the provisions of this guidance effective January 1, 2018. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In May 2017, the FASB issued Accounting Standards Update No. 2017-09, Compensation - Stock Compensation (Topic 718), Scope of Modification Accounting ("ASU 2017-09") , which amends the scope of modification accounting for share-based payment arrangements. ASU 2017-09 provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under Topic 718. Specifically, an entity would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. If an entity modifies its awards and concludes that it is not required to apply modification accounting under the standard, it must still consider whether the modification affects its application of other guidance. Additionally, if a significant modification does not result in incremental compensation cost, entities are required to disclose the “lack of” incremental compensation cost resulting from such significant modification. The standard also removes the guidance in Topic 718 stating that modification accounting is not required when an entity adds an antidilution provision as long as that modification is not made in contemplation of an equity restructuring. The provisions of this guidance are to be applied on a prospective basis to awards modified on or after the effective date. ASU 2017-09 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted, including adoption in any interim period. The Company adopted ASU 2017-09 effective January 1, 2018. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In March 2017, the FASB issued Accounting Standards Update No. 2017-07, Compensation - Retirement Benefits (Topic 715), Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost ("ASU 2017-07") , which amends the requirements in Topic 715 related to the income statement presentation of the components of net periodic benefit cost for an entity’s sponsored defined benefit pension and other postretirement plans. ASU 2017-07 requires entities to (1) disaggregate the current-service-cost component from the other components of net benefit cost (the “other components”) and present it with other current employee compensation costs in their income statements and (2) present the other components elsewhere in their income statements and outside of income from operations, and disclose the income statement lines that contain the other components if they are not presented on appropriately described separate lines. Additionally, the standard requires that only the service-cost component of net benefit cost is eligible for capitalization (e.g., as part of inventory or property, plant, and equipment). The change in income statement presentation requires retrospective application, while the change in capitalized benefit cost is to be applied prospectively. ASU 2017-07 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The standard provides a practical expedient that permits entities to use the components of cost disclosed in prior years as a basis for the retrospective application of the new income statement presentation. Entities need to disclose the use of the practical expedient. The Company adopted ASU 2017-07 effective January 1, 2018 using a retrospective approach for each period presented. For the three and six months ended July 2, 2017 , $1.8 million and $3.6 million , respectively, of net periodic pension credit previously presented within operating income has been presented outside of operating income in the line item "Interest and other expense, net" in the condensed consolidated statement of operations due to the retrospective adoption of ASU 2017-07. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows, other than the impact discussed above. In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (Topic 805), Clarifying the Definition of a Business ("ASU 2017-01"), which amends Topic 805 to provide a screen to determine when a set of assets and liabilities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. If the screen is not met, the standard (1) requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) removes the evaluation of whether a market participant could replace missing elements. The standard provides a framework to assist entities in evaluating whether both an input and a substantive process are present. The standard also provides a framework that includes two sets of criteria to consider that depend on whether a set has outputs and a more stringent criteria for sets without outputs. Lastly, the standard narrows the definition of the term "output" so that the term is consistent with how outputs are described in Topic 606, Revenue from Contracts with Customers . The provisions of this guidance are to be applied prospectively. ASU 2017-01 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted in limited circumstances. The Company adopted ASU 2017-01 effective January 1, 2018. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Statement of Cash Flows (Topic 230), Restricted Cash ("ASU 2016-18"), which amends Topic 230 to add or clarify guidance on the classification and presentation of restricted cash in the statement of cash flows. The standard requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The provisions of this guidance are to be applied using a retrospective transition method to each period presented. ASU 2016-18 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The Company adopted ASU 2016-18 effective January 1, 2018. For the six months ended July 2, 2017 , $17.2 million of changes in restricted cash balances that was previously presented within investing activities in the condensed consolidated statement of cash flows has been excluded from the cash flows used in investing activities and the effect of exchange rate changes increased by $0.2 million due to the retrospective adoption of ASU 2016-18. Restricted cash amounting to $17.3 million and $0.3 million at January 1, 2017 and July 2, 2017 , respectively, have been included with the cash and cash equivalents when reconciling the beginning of period and end of period total amounts on the condensed consolidated statement of cash flows for the six months ended July 2, 2017 . The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows, other than the impact discussed above. In October 2016, the FASB issued Accounting Standards Update No. 2016-16, Income Taxes (Topic 740), Intra-entity Transfer of Assets Other than Inventory ("ASU 2016-16"). ASU 2016-16 removes the prohibition in Topic 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. The standard requires entities to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The provisions of this guidance are to be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. ASU 2016-16 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The Company adopted ASU 2016-16 on January 1, 2018. The adoption of the standard resulted in a decrease in the retained earnings at January 1, 2018 of approximately $2.0 million with corresponding increase in deferred tax assets of $10.7 million and decrease in prepaid taxes of $12.8 million related to prior years’ intra-entity transfers of assets other than inventory. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows, other than the impact discussed above. In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"). ASU 2016-13 changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The standard requires entities to use the expected loss impairment model and will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases and off-balance sheet credit exposures. Entities are required to estimate the lifetime “expected credit loss” for each applicable financial asset and record an allowance that, when deducted from the amortized cost basis of the financial asset, presents the net amount expected to be collected on the financial asset. The standard also amends the impairment model for available-for-sale (“AFS”) debt securities and requires entities to determine whether all or a portion of the unrealized loss on an AFS debt security is a credit loss. An entity will recognize an allowance for credit losses on an AFS debt security as a contra-account to the amortized cost basis rather than as a direct reduction of the amortized cost basis of the investment. The provisions of this guidance are to be applied using a modified-retrospective approach. A prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. ASU 2016-13 is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years. Early adoption is permitted for annual periods beginning after December 15, 2018, and interim periods therein. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases ("ASU 2016-02"). ASU 2016-02 requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease of assets will primarily depend on its classification as a finance or operating lease. ASU 2016-02 also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The provisions of this guidance are effective for annual periods beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. ASU 2016-02 is to be applied using a modified retrospective approach. The Company is evaluating the requirements of this guidance and has not yet determined the impact of the adoption on its consolidated financial position, results of operations and cash flows. The Company does not intend to early adopt the provisions of this standard. In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). Under this new guidance, an entity should use a five-step process to recognize revenue, depicting the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires new disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. Subsequent to the issuance of the standard, the FASB decided to defer the effective date for one year to annual reporting periods beginning after December 15, 2017, with early adoption permitted for annual reporting periods beginning after December 15, 2016. In November 2017, the FASB also issued Accounting Standards Update No. 2017-14, Income Statement-Reporting Comprehensive Income (Topic 220), Revenue Recognition (Topic 605), and Revenue from Contracts with Customers (Topic 606) . ASU 2017-14 includes amendments to certain SEC paragraphs within the FASB Accounting Standards Codification ("Codification"). ASU 2017-14 amends the Codification to incorporate SEC Staff Accounting Bulletin No. 116 and SEC Interpretive Release on Vaccines for Federal Government Stockpiles (SEC Release No. 33-10403) to align existing SEC staff guidance with Revenue from Contracts with Customers (Topic 606). In May 2016, the FASB also issued Accounting Standards Update No. 2016-12, Revenue from Contracts with Customers (Topic 606), Narrow-Scope Improvements and Practical Expedients ("ASU 2016-12") , which amended its revenue recognition guidance in ASU 2014-09 on transition, collectability, non-cash consideration, contract modifications and completed contracts at transition and the presentation of sales and other similar taxes collected from customers. In April 2016, the FASB also issued Accounting Standards Update No. 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing ("ASU 2016-10") , which amended its revenue recognition guidance in ASU 2014-09 on identifying performance obligations to allow entities to disregard items that are immaterial in the context of the contract, clarify when a promised good or service is separately identifiable (i.e., distinct within the context of the contract) and allow an entity to elect to account for the cost of shipping and handling performed after control of a good has been transferred to the customer as a fulfillment cost (i.e., an expense). ASU 2016-10 also clarifies how an entity should evaluate the nature of its promise in granting a license of intellectual property ("IP") and requires entities to classify IP in one of two categories: functional IP or symbolic IP, which will determine whether it recognizes revenue over time or at a point in time. ASU 2016-10 also addresses how entities should consider license renewals and restrictions and apply the exception for sales- and usage-based royalties received in exchange for licenses of IP. In March 2016, the FASB also issued Accounting Standards Update No. 2016-08, Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net) ("ASU 2016-08"), which amended the principal-versus-agent implementation guidance and illustrations in ASU 2014-09. ASU 2016-08 clarifies that an entity should evaluate when it is the principal or agent for each specified good or service promised in a contract with a customer. ASU 2017-14, ASU 2016-12, ASU 2016-10, ASU 2016-08 and ASU 2014-09 may be adopted either using a full retrospective approach or a modified retrospective approach. The Company adopted these standards beginning on January 1, 2018 using the modified retrospective approach only to contracts not completed as of January 1, 2018 . The most significant impact of the standards relates to the accounting for certain transactions with multiple elements or “bundled” arrangements. Specifically, for sales of software subscriptions or sales of licenses and maintenance, the Company will recognize the license revenue predominantly at the time of billing and delivery rather than recognizing the entire sales price ratably over the maintenance period, which is the Company's current practice. In addition, for certain sales of instruments that include customer-specified acceptance criteria, the Company will recognize revenue when the customer obtains control of the instrument which is typically upon delivery or when title has transferred to the customer, as the Company believes acceptance is perfunctory. The Company will also capitalize incremental commission fees as a result of obtaining contracts when these fees are recoverable and will amortize the assets based on the transfer of goods or services to which the assets relate which typically range from two to six years. The adoption of the standards resulted in an increase in retained earnings at January 1, 2018 of approximately $10.2 million for the cumulative effect of initially applying the standards as of that date. In addition, the adoption of the standards resulted primarily in a reduction in deferred revenue of approximately $11.5 million , mainly driven by the upfront recognition of license revenue and certain multi-year software subscriptions, and an increase in deferred income tax liability of approximately $3.0 million for the tax impact of the cumulative adjustments. The cumulative effect of recognizing instrument sales upon delivery or transfer of title and capitalizing the incremental commission fees were not material at January 1, 2018. The adoption of the standards had no impact to cash from or used in operating, investing, or financing activities in the Company's consolidated statement of cash flows at January 1, 2018. Refer to Note 3, Changes in Accounting Policies, for the impact of adoption of the standards on the Company's condensed consolidated financial statements for the quarter ended July 1, 2018 . Also refer to Note 2, Revenue, for the disclosures required by the standards.

Revenue (Notes)

Revenue (Notes) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Revenue [Abstract]
Revenue from Contract with Customer [Text Block]			Revenue Significant accounting policy The Company enters into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. The Company recognizes revenue in an amount that reflects the consideration the Company expects to receive in exchange for the promised products or services when it satisfies a performance obligation by transferring control of those products or services to customers. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. The Company reports shipping and handling charges in revenue, to the extent these are billed to customers, and the associated costs in cost of product revenue. Nature of goods and services The following is a description of principal activities - separated by reportable segments - from which the Company generates its revenue. For more detailed information about the reportable segments, see Note 12. i. Discovery & Analytical Solutions The Discovery & Analytical Solutions ("DAS") segment of the Company principally generates revenue from (a) sales of instruments, consumables and services in the applied markets, (b) sales of instruments, reagents, informatics, detection and imaging technologies, extended warranty, training and services in the life sciences market. Products and services may be sold separately or in bundled packages. The typical length of a contract for service is 12 to 36 months. For bundled packages, the Company accounts for individual products and services separately if they are distinct - i.e. if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The consideration (including any discounts) is allocated between separate products and services in a bundle based on their stand-alone selling prices. The stand-alone selling prices are determined based on the prices at which the Company separately sells the products, extended warranties, and services. For items that are not sold separately, the Company estimates stand-alone selling prices by reference to the amount charged for similar items on a stand-alone basis. The Company sells products and services predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including distributors. Payment terms granted to distributors are the same as those granted to end-customers and payments are not dependent upon the distributor's receipt of payment from their end-user customers. In instances where the timing of revenue recognition differs from the timing of invoicing, the Company determined that the contracts generally do not include a significant financing component. The primary purpose of its invoicing terms is to provide customers with simplified and predictable ways of purchasing products and services, rather than to receive financing from the customers or to provide customers with financing. Examples include invoicing at the beginning of a subscription term with revenue recognized ratably over the contract period, and multi-year software licenses or software subscriptions that are invoiced annually with revenue recognized upfront. In limited circumstances where the Company provides the customer with a significant benefit of financing, the Company uses the practical expedient and only adjusts the transaction price for the effects of the time value of money and only on contracts where the duration of financing is more than one year. Products and services Nature, timing of satisfaction of performance obligations, and significant payment terms Instruments For instruments that include installation, and if the installation meets the criteria to be considered a separate performance obligation, product revenue is generally recognized upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers, and installation revenue is recognized when the installation is complete. Certain of the Company's products require specialized installation and configuration at the customer's site. Revenue for these products is deferred until installation is complete and customer acceptance has been received. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 60 days. Consumables and reagents The Company recognizes revenue from the sale of consumables and reagents upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 days. Software licenses and subscriptions Customers may purchase perpetual or term licenses, or subscribe to licenses, which provide customers with the same functionality and differ mainly in the duration over which the customer benefits from the software. The Company sells its software subscriptions or software licenses with maintenance services and, in some cases, with consulting services. The Company recognizes revenue for the software upfront at the point in time when the software is made available to the customer. For maintenance and consulting services, revenue is recognized ratably over the period in which the services are provided. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 60 days. Software subscriptions and maintenance service contracts are non-cancelable. Cloud services Cloud services, which allow customers to use hosted software over the contract period without taking possession of the software, are provided on either a subscription or consumption basis. Revenue related to cloud services provided on a subscription basis is recognized ratably over the contract period. Revenue related to cloud services provided on a consumption basis, such as the amount of storage used in a period, is recognized based on the customer utilization of such resources. Payment terms are generally net 30 days from signing of contract and contracts are non-cancelable. Extended warranty The Company recognizes revenue for extended warranties on a straight-line basis over the extended warranty period in service revenue. In the majority of countries in which the Company operates, the customary warranty period is one year and the extended warranty covers periods beyond year one. Customers typically pay for extended warranties on an annual basis over the term of the warranty. In general, customers can cancel the extended warranty at any time with 30 days notice without significant penalty. Laboratory services and training The Company's service offerings include service contracts, field service, including related time and materials, and training. The Company recognizes revenue as the services are performed. Revenue for the service contracts is recognized over the contract period or at a point in time when the service is billable based on time and materials. The Company recognizes revenue as training is provided in service revenue. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 60 days. In general, customers can cancel the service contracts at any time with 30 to 90 days notice without significant penalty. ii. Diagnostics The Diagnostics segment of the Company principally generates revenue from sales of instruments, solutions, consumables, reagents, extended warranty and services in the diagnostics market. Products and services may be sold separately or in bundled packages. For bundled packages, the Company accounts for individual products and services separately if they are distinct - i.e. if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The consideration (including any discounts) is allocated between separate products and services in a bundle based on their stand-alone selling prices. The stand-alone selling prices are determined based on the prices at which the Company separately sells the products, extended warranties, and services. For items that are not sold separately, the Company estimates stand-alone selling prices by reference to the amount charged for similar items on a stand-alone basis. The Company sells products and services predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including distributors. Payment terms granted to distributors are the same as those granted to end-customers and payments are not dependent upon the distributor's receipt of payment from their end-user customers. In instances where the timing of revenue recognition differs from the timing of invoicing, the Company determined that the contracts generally do not include a significant financing component. The primary purpose of its invoicing terms is to provide customers with simplified and predictable ways of purchasing products and services, rather than to receive financing from the customers or to provide customers with financing. Examples include invoicing at the beginning of a storage period with revenue recognized ratably over the contract period. In limited circumstances where the Company provides the customer with a significant benefit of financing, the Company uses the practical expedient and only adjusts the transaction price for the effects of the time value of money and only on contracts where the duration of financing is more than one year. Products and services Nature, timing of satisfaction of performance obligations, and significant payment terms Instruments For instruments that include installation, and if the installation meets the criteria to be considered a separate performance obligation, product revenue is generally recognized upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers, and installation revenue is recognized when the installation is complete. Certain of the Company's products require specialized installation and configuration at the customer's site. Revenue for these products is deferred until installation is complete and customer acceptance has been received. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 60 days. Consumables and reagents The Company recognizes revenue from the sale of consumables and reagents upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 days. Solutions When the Company sells the instrument and reagents that work only on those instruments to a customer or distributor, the Company considers the instrument and reagents as separate performance obligations. The Company recognizes revenue when an instrument is sold to the customer upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers. Revenue from the sale of reagents are also recognized at the time of delivery or when title has transferred to the customer. Payment terms for instrument and reagent sales are usually net 30 days from invoice date. When the Company places the instrument at the customer's site and sells the reagents to a customer, the instrument and reagents are accounted for together as one performance obligation. The Company does not charge a fee for the use of the instrument and retains ownership of the placed instrument. The Company has a right to remove the instrument and replace it with another instrument at the customer's site at any time throughout the contract term. The Company recognizes revenue upon delivery of reagents, which is the point in time where the Company has performed its obligation to provide a screening solution to the customer. Payment terms are usually net 30 days from invoice date. Payment terms for certain contracts are based on equal installments over the duration of the contract. Extended warranty The Company recognizes revenue for extended warranties on a straight-line basis over the extended warranty period in service revenue. In the majority of countries in which the Company operates, the customary warranty period is one year and the extended warranty covers periods beyond year one. Customers typically pay for extended warranties on an annual basis over the term of the warranty. In general, customers can cancel the extended warranty at any time with 30 days notice without significant penalty. Services The Company's service offerings include cord blood processing and storage, and training. The Company recognizes revenue for the cord blood processing and training as the services are performed in service revenue. Revenue for the storage contracts are recognized over the contract period. Storage is typically for a period of 1, 20, or 25 years or lifetime. Lifetime storage is recognized over a certain period that is based on the life expectancy estimate from Social Security data. For cord blood processing, customers pay the processing fee in full at the point of sale. The processing fee is non-refundable unless the cord blood is non-viable for storage. For storage, customers are required to pay the storage fees in full upfront. Storage fees are refundable to the customer on a pro-rated basis if the contract is canceled. Disaggregation of revenue In the following tables, revenue is disaggregated by primary geographical market, end-markets and timing of revenue recognition. The tables also include a reconciliation of the disaggregated revenue with the reportable segments revenue. Reportable Segments Three Months Ended July 1, 2018 Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 170,973 $ 98,395 $ 269,368 Europe 127,646 69,700 197,346 Asia 132,009 104,639 236,648 $ 430,628 $ 272,734 $ 703,362 Primary end-markets Diagnostics $ — $ 272,734 $ 272,734 Life sciences 233,906 — 233,906 Applied markets 196,722 — 196,722 $ 430,628 $ 272,734 $ 703,362 Timing of revenue recognition Products and services transferred at a point in time $ 312,815 $ 252,401 $ 565,216 Services transferred over time 117,813 20,333 138,146 $ 430,628 $ 272,734 $ 703,362 Reportable Segments Six Months Ended July 1, 2018 Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 328,467 $ 186,929 $ 515,396 Europe 247,019 137,412 384,431 Asia 251,667 195,840 447,507 $ 827,153 $ 520,181 $ 1,347,334 Primary end-markets Diagnostics $ — $ 520,181 $ 520,181 Life sciences 453,616 — 453,616 Applied markets 373,537 — 373,537 $ 827,153 $ 520,181 $ 1,347,334 Timing of revenue recognition Products and services transferred at a point in time $ 583,588 $ 478,869 $ 1,062,457 Services transferred over time 243,565 41,312 284,877 $ 827,153 $ 520,181 $ 1,347,334 Contract Balances Contract assets: The unbilled receivables (contract assets) primarily relate to the Company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are transferred to trade receivables when billed to customers. Contracts assets are generally classified as current assets and are included in "Accounts receivable, net" in the consolidated balance sheet. The balance of contract assets as of July 1, 2018 and as of the date of adoption of ASC 606 were $28.4 million and $22.7 million , respectively. The amount of unbilled receivables recognized at the beginning of the period that were transferred to trade receivables during the six months ended July 1, 2018 was $31.1 million . The increase in unbilled receivables during the six months ended July 1, 2018 as a result of recognition of revenue before billing to customers, excluding amounts transferred to trade receivables during the period, amounted to $36.7 million . Contract liabilities: The contract liabilities primarily relate to the advance consideration received from customers for products and related installation for which transfer of control has not occurred at the balance sheet date. Contract liabilities are classified as either current in "Accounts payable" or long-term in "Long-term liabilities" in the consolidated balance sheet based on the timing of when the Company expects to recognize revenue. The balance of contract liabilities as of July 1, 2018 and as of the date of adoption of ASC 606 were $26.9 million and $29.0 million , respectively. The increase in contract liabilities during the six months ended July 1, 2018 due to cash received, excluding amounts recognized as revenue during the period, was $36.1 million . The amount of revenue recognized during the six months ended July 1, 2018 that was included in the contract liability balance at the beginning of the period was $38.2 million . Contract costs: The Company recognizes the incremental costs of obtaining a contract with a customer as an asset if it expects the benefit of those costs to be longer than one year. The Company determined that certain sales incentive programs meet the requirements to be capitalized. Total capitalized costs to obtain a contract were immaterial during the period and are included in other current and long-term assets on the condensed consolidated balance sheet. The Company applies a practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the Company's internal sales force compensation program, as the Company determined that annual compensation is commensurate with annual sales activities. Transaction price allocated to the remaining performance obligations The Company applies the practical expedient in ASC 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized beyond one year in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. Remaining performance obligations primarily include noncancelable purchase orders and noncancelable software subscriptions and cloud service contracts.
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 703,362	$ 546,962	$ 1,347,334	$ 1,061,077
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	565,216		1,062,457
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	138,146		284,877
Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	269,368		515,396
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	197,346		384,431
Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	236,648		447,507
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	272,734		520,181
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	233,906		453,616
Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	196,722		373,537
Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	430,628	383,128	827,153	744,888
Discovery & Analytical Solutions [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	312,815		583,588
Discovery & Analytical Solutions [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	117,813		243,565
Discovery & Analytical Solutions [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	170,973		328,467
Discovery & Analytical Solutions [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	127,646		247,019
Discovery & Analytical Solutions [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	132,009		251,667
Discovery & Analytical Solutions [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0		0
Discovery & Analytical Solutions [Member] | Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	233,906		453,616
Discovery & Analytical Solutions [Member] | Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	196,722		373,537
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	272,734	$ 163,834	520,181	$ 316,189
Diagnostics [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	252,401		478,869
Diagnostics [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	20,333		41,312
Diagnostics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	98,395		186,929
Diagnostics [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	69,700		137,412
Diagnostics [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	104,639		195,840
Diagnostics [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	272,734		520,181
Diagnostics [Member] | Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0		0
Diagnostics [Member] | Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 0		$ 0

Changes in Accounting Policies

Changes in Accounting Policies (Notes)	6 Months Ended
	Jul. 01, 2018
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies [Text Block]	Changes in Accounting Policies Except for the changes below, the Company has consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements. The Company adopted ASC 606, Revenue from Contracts with Customers ("ASC 606"), with a date of the initial application of January 1, 2018. As a result, the Company has changed its accounting policy for revenue recognition as detailed below. The Company applied ASC 606 using the modified retrospective method only to contracts that are not completed contracts as of January 1, 2018, and the cumulative effect of initially applying ASC 606 is recognized as an adjustment to the beginning retained earnings. Therefore, the comparative information has not been adjusted and continues to be reported under ASC 605. The details of the significant changes and quantitative impact of the changes are disclosed below. A. Sales of software subscriptions or sales of licenses and maintenance in bundled arrangements The Company previously recognized revenue from software licenses sold together with maintenance and/or consulting services upon shipment using the residual method, provided that the undelivered items in the arrangement have value to the customer on a stand-alone basis and vendor-specific objective evidence ("VSOE") of fair value can be determined. If VSOE of fair value for the undelivered elements cannot be established, the Company deferred all revenue from the arrangement until the earlier of the point at which such sufficient VSOE does exist or all elements of the arrangement have been delivered, or if the undelivered element is maintenance, then the Company recognized the entire fee ratably over the maintenance period. Under ASC 606, the total consideration in the contract is allocated to all products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the list prices at which the Company sells the software license, software subscription, maintenance and/or consulting services. Accordingly, the Company now recognizes higher license revenue upfront and less service revenue over time. B. Sales of instruments The Company previously recognized revenue from sale of instruments when persuasive evidence of an arrangement existed, delivery had occurred, the price to the buyer was fixed or determinable, and collectability was reasonably assured. For certain sales of instruments that included customer-specified acceptance criteria, the Company previously recognized revenue after the acceptance criteria had been met. Under ASC 606, revenue is recognized when the Company satisfies a performance obligation by transferring control of the product to a customer. Accordingly, the Company now recognizes product revenue upon delivery or when title has transferred to the customer, as the Company believes acceptance is perfunctory. C. Sales commissions The Company previously recognized commission fees related to sales of products and services as selling expenses when they were incurred. Under ASC 606, the Company capitalizes those commission fees as costs of obtaining a contract, when they are incremental and, if they are expected to be recovered, the Company amortizes them consistently with the pattern of transfer of the product or service to which the asset relates. If the expected amortization period is one year or less, the commission fee is expensed when incurred. D. Impacts on financial statements The following tables summarize the impacts of ASC 606 adoption on the Company's condensed consolidated financial statements for the quarter ended July 1, 2018 . Consolidated Balance Sheet As reported Adjustments Balances without adoption of ASC 606 (In thousands) Cash and cash equivalents $ 163,392 $ — $ 163,392 Accounts receivable, net 564,041 (12,505 ) 551,536 Inventories 366,961 7,556 374,517 Other current assets 108,019 (679 ) 107,340 Property, plant and equipment, net 304,538 — 304,538 Intangible assets, net 1,270,867 — 1,270,867 Goodwill 2,940,825 — 2,940,825 Other assets, net 239,135 — 239,135 Total assets $ 5,957,778 $ (5,628 ) $ 5,952,150 Current portion of long-term debt $ 17,315 $ — $ 17,315 Accounts payable 197,128 — 197,128 Accrued restructuring and contract termination charges 7,443 — 7,443 Accrued expenses and other current liabilities 488,642 15,577 504,219 Current liabilities of discontinued operations 2,165 — 2,165 Long-term debt 1,983,953 — 1,983,953 Long-term liabilities 743,955 — 743,955 Total liabilities 3,440,601 15,577 3,456,178 Commitments and contingencies Preferred stock — — — Common stock 110,716 — 110,716 Capital in excess of par value 73,740 — 73,740 Retained earnings 2,463,287 (21,205 ) 2,442,082 Accumulated other comprehensive loss (130,566 ) — (130,566 ) Total stockholders’ equity 2,517,177 (21,205 ) 2,495,972 Total liabilities and stockholders’ equity $ 5,957,778 $ (5,628 ) $ 5,952,150 Consolidated Statement of Operations Three Months Ended July 1, 2018 As reported Adjustments Balances without adoption of ASC 606 (In thousands) Product revenue $ 495,608 $ (9,178 ) $ 486,430 Service revenue 207,754 — 207,754 Total revenue 703,362 (9,178 ) 694,184 Cost of product revenue 229,723 (3,566 ) 226,157 Cost of service revenue 133,499 — 133,499 Total cost of revenue 363,222 (3,566 ) 359,656 Selling, general and administrative expenses 204,880 74 204,954 Research and development expenses 47,196 — 47,196 Operating income from continuing operations 88,064 (5,686 ) 82,378 Interest and other expense, net 16,356 — 16,356 Income from continuing operations before income taxes 71,708 (5,686 ) 66,022 Provision for income taxes 7,035 (1,499 ) 5,536 Income from continuing operations 64,673 (4,187 ) 60,486 Loss on disposition of discontinued operations before income taxes (551 ) — (551 ) Provision for income taxes on discontinued operations and dispositions 59 — 59 Loss from discontinued operations and dispositions (610 ) — (610 ) Net income $ 64,063 $ (4,187 ) $ 59,876 Consolidated Statement of Operations Six Months Ended July 1, 2018 As reported Adjustments Balances without adoption of ASC 606 (In thousands) Product revenue $ 943,216 $ (22,364 ) $ 920,852 Service revenue 404,118 — 404,118 Total revenue 1,347,334 (22,364 ) 1,324,970 Cost of product revenue 449,979 (7,682 ) 442,297 Cost of service revenue 264,993 — 264,993 Total cost of revenue 714,972 (7,682 ) 707,290 Selling, general and administrative expenses 404,605 253 404,858 Research and development expenses 93,180 — 93,180 Restructuring and contract termination charges, net 6,578 — 6,578 Operating income from continuing operations 127,999 (14,935 ) 113,064 Interest and other expense, net 27,786 — 27,786 Income from continuing operations before income taxes 100,213 (14,935 ) 85,278 Provision for income taxes 9,505 (3,939 ) 5,566 Income from continuing operations 90,708 (10,996 ) 79,712 Loss on disposition of discontinued operations before income taxes (551 ) — (551 ) Provision for income taxes on discontinued operations and dispositions 70 — 70 Loss from discontinued operations and dispositions (621 ) — (621 ) Net income $ 90,087 $ (10,996 ) $ 79,091 The adoption of ASC 606 increased comprehensive income by $4.2 million and $11.0 million in the Company's condensed consolidated statement of comprehensive income for the three and six months ended July 1, 2018 , respectively. The adoption of ASC 606 had no impact on cash from or used in operating, investing, or financing activities in the Company's condensed consolidated statement of cash flows as of and for the six months ended July 1, 2018 .

Business Combinations

Business Combinations	6 Months Ended
	Jul. 01, 2018
Business Combinations [Abstract]
Business Combinations	Business Combinations Acquisitions in fiscal year 2018 During fiscal year 2018 , the Company completed the acquisition of two businesses for aggregate consideration of $38.9 million . The acquired businesses were Shanghai Spectrum Instruments Co., Ltd. ("SSI"), which was acquired for total consideration of $15.4 million in cash, and RHS Limited ("RHS"), which was acquired for total consideration of $19.4 million in cash. The Company has an obligation to pay the former shareholders of SSI an additional consideration of $2.5 million in fiscal year 2019, which at closing had a present value of $2.4 million . The Company also has a potential obligation to pay the former shareholders of SSI additional contingent consideration of up to $2.0 million , which at closing had an estimated fair value of $1.7 million . The excess of the purchase price over the fair value of the acquired business' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, which is not tax deductible. The Company has reported the operations for SSI within the results of the Company's DAS segment and the other acquisition within the results of the Company's Diagnostics segment from the acquisition dates. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of these acquisitions had a weighted average amortization period of 12.0 years . The total purchase price for the acquisitions in fiscal year 2018 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: 2018 Acquisitions (In thousands) Fair value of business combination: Cash payments $ 34,942 Other liability 2,354 Contingent consideration 1,700 Working capital and other adjustments (101 ) Less: cash acquired (370 ) Total $ 38,525 Identifiable assets acquired and liabilities assumed: Current assets $ 2,750 Property, plant and equipment 311 Identifiable intangible assets: Core technology 15,957 Trade names 610 Customer relationships 5,100 Goodwill 19,793 Deferred taxes (2,523 ) Liabilities assumed (3,473 ) Total $ 38,525 Acquisitions in fiscal year 2017 Acquisition of EUROIMMUN Medizinische Labordiagnostika AG. During fiscal year 2017 , the Company completed the acquisition of 99.98% of the outstanding stock of EUROIMMUN Medizinische Labordiagnostika AG (“EUROIMMUN”) for aggregate consideration of €1.2 billion (equivalent to $1.4 billion at December 19, 2017, the time of closing). The purchase price was funded by borrowings from the Company's senior unsecured revolving credit facility and senior unsecured term loan credit facility of $710.0 million and $200.0 million , respectively, and available cash on hand of $503.8 million . EUROIMMUN is based in Lübeck, Germany, has approximately 2,400 employees, and is recognized as a global leader in autoimmune testing and an emerging force in infectious disease and allergy testing. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired. As a result of the acquisition, the Company recorded goodwill of $582.7 million , which is not tax deductible, and intangible assets of $907.4 million . The Company has reported the operations for this acquisition within the results of the Company's Diagnostics segment from the acquisition date. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of this acquisition had a weighted average amortization period of 16.1 years . Other acquisitions in 2017. During fiscal year 2017, the Company also completed the acquisition of two other businesses for aggregate consideration of $142.0 million . The acquired businesses were Tulip Diagnostics Private Limited (“Tulip”), which was acquired for total consideration of $127.3 million in cash and one other business acquired for total consideration of $14.7 million in cash. At the time of closing, the Company had a potential obligation to pay the former shareholders of Tulip up to INR 1.6 billion , equivalent to $25.2 million , in additional consideration over a two year period that is accounted for as compensation expense in the Company's financial statements over a two year period and is excluded from the purchase price allocation shown below. The excess of the purchase prices over the fair values of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. The Company has reported the operations of Tulip within the results of the Company's Diagnostics segment and the other acquired business within the results of the Company's DAS segment from the acquisition date. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of these acquisitions had a weighted average amortization period of 11.8 years . During the first quarter of fiscal year 2018, the Company paid the former shareholders of Tulip a portion of the additional consideration amounting to INR 716.3 million (equivalent to $11.3 million ). As of July 1, 2018 , the Company may have to pay the former shareholders of Tulip additional consideration of up to INR 803.6 million (currently equivalent to $11.7 million ) in the first quarter of fiscal year 2019. The total purchase price for the acquisitions in fiscal year 2017 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: EUROIMMUN Other Acquisitions (In thousands) Fair value of business combination: Cash payments $ 1,413,780 $ 140,861 Other liability — 1,273 Working capital and other adjustments — (93 ) Less: cash acquired (25,018 ) (2,439 ) Total $ 1,388,762 $ 139,602 Identifiable assets acquired and liabilities assumed: Current assets $ 121,174 $ 16,268 Property, plant and equipment 129,964 11,356 Other assets 49,944 1,691 Identifiable intangible assets: Core technology 160,000 12,400 Trade names 36,000 3,000 Customer relationships 710,000 43,700 In-process research and development ("IPR&D") 1,400 — Goodwill 582,692 75,250 Deferred taxes (253,354 ) (15,735 ) Liabilities assumed (87,701 ) (8,328 ) Debt assumed (61,357 ) — Total $ 1,388,762 $ 139,602 EUROIMMUN's revenue and net loss for the period from the acquisition date to December 31, 2017 were $13.5 million and $1.0 million , respectively. The following unaudited pro forma information presents the combined financial results for the Company and EUROIMMUN as if the acquisition of EUROIMMUN had been completed at the beginning of fiscal year 2016: Three Months Ended July 2, 2017 Six Months Ended July 2, 2017 (In thousands, except per share data) Pro Forma Statement of Operations Information (Unaudited): Revenue $ 625,525 $ 1,206,079 Income from continuing operations 53,024 78,617 Basic earnings per share: Income from continuing operations $ 0.48 $ 0.72 Diluted earnings per share: Income from continuing operations $ 0.48 $ 0.71 The unaudited pro forma information for the three and six months ended July 2, 2017 has been calculated after applying the Company's accounting policies and the impact of acquisition date fair value adjustments. These pro forma condensed consolidated financial results have been prepared for comparative purposes only and include certain adjustments, such as increased interest expense on debt obtained to finance the transaction and increased amortization for the acquired intangible assets recorded at fair value. The pro forma information does not reflect the effect of costs or synergies that would have been expected to result from the integration of the acquisition. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combination occurred at the beginning of each period presented, or of future results of the consolidated entities. The preliminary allocations of the purchase prices for acquisitions are based upon initial valuations. The Company's estimates and assumptions underlying the initial valuations are subject to the collection of information necessary to complete its valuations within the measurement periods, which are up to one year from the respective acquisition dates. The primary areas of the preliminary purchase price allocations that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition dates during the measurement periods. During the measurement periods, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition dates that, if known, would have resulted in the recognition of those assets and liabilities as of those dates. These adjustments will be made in the periods in which the amounts are determined and the cumulative effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition dates. All changes that do not qualify as adjustments made during the measurement periods are also included in current period earnings. Allocations of the purchase price for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds, changes in discount rates or product development milestones during the earnout period. During the second quarter of fiscal year 2018 , the Company obtained information relevant to determining the fair values of certain tangible and intangible assets acquired, and liabilities assumed, related to recent acquisitions and adjusted its purchase price allocation. Based on this information, for the EUROIMMUN acquisition, the Company recognized a decrease in liabilities assumed of $1.0 million , an increase in deferred tax liabilities of $2.9 million , an increase in intangible assets of $10.0 million and a decrease in goodwill of $8.1 million during the second quarter of fiscal year 2018 . As of July 1, 2018 , the Company may have to pay contingent consideration related to acquisitions with open contingency periods of up to $85.0 million . As of July 1, 2018 , the Company has recorded contingent consideration obligations with an estimated fair value of $74.1 million , of which $67.5 million was recorded in accrued expenses and other current liabilities, and $6.6 million was recorded in long-term liabilities. As of December 31, 2017 , the Company had recorded contingent consideration obligations with an estimated fair value of $65.3 million , of which $52.2 million was recorded in accrued expenses and other current liabilities, and $13.1 million was recorded in long-term liabilities. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the condensed consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets or the recognition of additional contingent consideration which would be recognized as a component of operating expenses from continuing operations. Total transaction costs related to acquisition and divestiture activities for the three and six months ended July 1, 2018 were $1.6 million and $4.2 million , respectively. Total transaction costs related to acquisition and divestiture activities for the three and six months ended July 2, 2017 were $3.7 million and $6.3 million , respectively. These transaction costs were expensed as incurred and recorded in selling, general and administrative expenses in the Company's condensed consolidated statements of operations.

Discontinued Operations

Discontinued Operations	6 Months Ended
	Jul. 01, 2018
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Disposition of Businesses and Assets As part of the Company’s continuing efforts to focus on higher growth opportunities, the Company has discontinued certain businesses. When the discontinued operations represented a strategic shift that will have a major effect on the Company's operations and financial statements, the Company has accounted for these businesses as discontinued operations and accordingly, has presented the results of operations and related cash flows as discontinued operations. Any business deemed to be a discontinued operation prior to the adoption of ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of An Entity, continues to be reported as a discontinued operation, and the results of operations and related cash flows are presented as discontinued operations for all periods presented. Any remaining assets and liabilities of these businesses have been presented separately, and are reflected within assets and liabilities of discontinued operations in the accompanying condensed consolidated balance sheets as of July 1, 2018 and December 31, 2017 . On May 1, 2017 (the "Varex Closing Date"), the Company completed the sale of its Medical Imaging business to Varex Imaging Corporation ("Varex") pursuant to the terms of the Master Purchase and Sale Agreement, dated December 21, 2016 (the “Agreement”), by and between the Company and Varian Medical Systems, Inc. ("Varian") and the subsequent Assignment and Assumption Agreement, dated January 27, 2017, between Varian and Varex, pursuant to which Varian assigned its rights under the Agreement to Varex. On the Varex Closing Date, the Company received consideration of approximately $277.4 million for the sale of the Medical Imaging business. During fiscal year 2017, the Company paid Varex $4.2 million to settle a post-closing working capital adjustment. During fiscal year 2017, the Company recorded a pre-tax gain of $179.6 million and income tax expense of $43.1 million related to the sale of the Medical Imaging business in discontinued operations and dispositions. The corresponding tax liability was recorded within the other tax liabilities in the condensed consolidated balance sheet, and the Company expects to utilize tax attributes to minimize the tax liability. Following the closing, the Company provided certain customary transitional services during a period of up to 12 months . Commercial transactions between the parties following the closing of the transaction are not expected to be significant. During fiscal year 2017, the Company sold Suzhou PerkinElmer Medical Laboratory Co., Ltd. for aggregate consideration of $2.3 million , recognizing a pre-tax loss of $1.1 million . The pre-tax loss recognized in fiscal year 2017 is included in interest and other expense, net in the consolidated statement of operations. Suzhou PerkinElmer Medical Laboratory Co., Ltd. was a component of the Company's Diagnostics segment. The divestiture of Suzhou PerkinElmer Medical Laboratory Co., Ltd. has not been classified as a discontinued operation in this Form 10-Q because the disposition does not represent a strategic shift that will have a major effect on the Company's operations and financial statements. The summary pre-tax operating results of the discontinued operations, were as follows for the three and six months ended: Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Revenue $ — $ 8,249 $ — $ 44,343 Cost of revenue — 8,138 — 32,933 Selling, general and administrative expenses — 1,926 — 5,869 Research and development expenses — 1,294 — 4,891 (Loss) income from discontinued operations before income taxes $ — $ (3,109 ) $ — $ 650

Restructuring and Lease Charges

Restructuring and Lease Charges, Net	6 Months Ended
	Jul. 01, 2018
Restructuring and Related Activities [Abstract]
Restructuring and Lease Charges, Net	Restructuring and Contract Termination Charges, Net The Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of the Company's operations with its growth strategy, the integration of its business units and its productivity initiatives. The current portion of restructuring and contract termination charges is recorded in accrued restructuring and contract termination charges and the long-term portion of restructuring and contract termination charges is recorded in long-term liabilities. The activities associated with these plans have been reported as restructuring and contract termination charges, net, as applicable, and are included as a component of income from continuing operations. The Company implemented a restructuring plan in the first quarter of fiscal year 2018 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q1 2018 Plan"). The Company implemented a restructuring plan in each of the fourth and third quarters of fiscal year 2017 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q4 2017 Plan and "Q3 2017 Plan", respectively). The Company implemented a restructuring plan in the first quarter of fiscal year 2017 consisting of workforce reductions and the closure of excess facility space principally intended to focus resources on higher growth end markets (the "Q1 2017 Plan"). Details of the plans initiated in previous years (the “Previous Plans”) are discussed more fully in Note 4 to the audited consolidated financial statements in the 2017 Form 10-K. The following table summarizes the reductions in headcount, the initial restructuring or contract termination charges by reporting segment, and the dates by which payments were substantially completed, or the dates by which payments are expected to be substantially completed, for restructuring actions implemented during fiscal years 2018 and 2017 in continuing operations: Workforce Reductions Closure of Excess Facility Total (Expected) Date Payments Substantially Completed by Headcount Reduction Discovery & Analytical Solutions Diagnostics Discovery & Analytical Solutions Diagnostics Severance Excess Facility (In thousands, except headcount data) Q1 2018 Plan 47 $ 5,096 $ 902 $ — $ — $ 5,998 Q2 FY2019 — Q4 2017 Plan 29 1,680 255 — — 1,935 Q1 FY2019 — Q3 2017 Plan 27 1,321 1,021 — — 2,342 Q4 FY2018 — Q1 2017 Plan 90 5,000 1,631 33 33 6,697 Q4 FY2018 Q4 FY2018 The Company does not currently expect to incur any future charges for these plans. The Company expects to make payments under the Previous Plans for remaining residual lease obligations, with terms varying in length, through fiscal year 2022 . In connection with the termination of various contractual commitments, the Company recorded additional pre-tax charges of $0.2 million during the six months ended July 1, 2018 in the DAS segment. At July 1, 2018 , the Company had $12.2 million recorded for accrued restructuring and contract termination charges, of which $7.4 million was recorded in short-term accrued restructuring and contract termination charges, $1.9 million was recorded in long-term liabilities, and $2.9 million was recorded in other reserves. At December 31, 2017 , the Company had $14.0 million recorded for accrued restructuring and contract termination charges, of which $8.8 million was recorded in short-term accrued restructuring and contract termination charges, $2.3 million was recorded in long-term liabilities and $2.9 million was recorded in other reserves. The following table summarizes the Company's restructuring and contract termination accrual balances and related activity by restructuring plan, as well as contract termination accrual balances and related activity, during the six months ended July 1, 2018 : Balance at December 31, 2017 2018 Charges 2018 Changes in Estimates, Net 2018 Amounts Paid Balance at July 1, 2018 (In thousands) Severance: Q1 2018 Plan $ — $ 5,998 $ — $ (3,606 ) $ 2,392 Q4 2017 Plan 1,919 — — (1,316 ) 603 Q3 2017 Plan 2,072 — — (863 ) 1,209 Q1 2017 Plan 2,498 — — (1,073 ) 1,425 Facility: Q1 2017 Plan 33 — — (22 ) 11 Previous Plans 4,399 — 353 (1,435 ) 3,317 Restructuring 10,921 5,998 353 (8,315 ) 8,957 Contract Termination 3,048 — 227 — 3,275 Total Restructuring and Contract Termination $ 13,969 $ 5,998 $ 580 $ (8,315 ) $ 12,232

Interest and Other Expense (Inc

Interest and Other Expense (Income), Net	6 Months Ended
	Jul. 01, 2018
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and Other Expense, Net Interest and other expense, net, consisted of the following: Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Interest income $ (173 ) $ (490 ) $ (438 ) $ (710 ) Interest expense 16,411 10,672 34,061 21,536 Loss on disposition of businesses and assets, net — 301 — 301 Other expense (income), net 118 (7,092 ) (5,837 ) (7,908 ) Total interest and other expense, net $ 16,356 $ 3,391 $ 27,786 $ 13,219 Foreign currency transaction losses (gains) were $12.9 million and $(13.1) million for the three and six months ended July 1, 2018 , respectively. Foreign currency transaction gains were $1.2 million and $2.7 million for the three and six months ended July 2, 2017 , respectively. Net (gains) losses from forward currency hedge contracts were $(10.3) million and $12.3 million for the three and six months ended July 1, 2018 , respectively. Net gains from forward currency hedge contracts were $4.1 million and $1.7 million for the three and six months ended July 2, 2017 , respectively. The other components of net periodic pension credit were $2.5 million and $5.0 million for the three and six months ended July 1, 2018 , respectively. The other components of net periodic pension credit were $1.8 million and $3.6 million for the three and six months ended July 2, 2017 , respectively. These amounts were included in other income, net.

Inventories, Net

Inventories, Net	6 Months Ended
	Jul. 01, 2018
Inventory Disclosure [Abstract]
Inventories, Net	Inventories Inventories as of July 1, 2018 and December 31, 2017 consisted of the following: July 1, December 31, (In thousands) Raw materials $ 128,927 $ 122,100 Work in progress 21,376 18,452 Finished goods 216,658 211,123 Total inventories $ 366,961 $ 351,675

Income Taxes

Income Taxes	6 Months Ended
	Jul. 01, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company regularly reviews its tax positions in each significant taxing jurisdiction in the process of evaluating its unrecognized tax benefits. The Company makes adjustments to its unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in management’s judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position. The total provision for income taxes included in the condensed consolidated statement of operations consisted of the following: Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Continuing operations $ 7,035 $ 8,066 $ 9,505 $ 11,987 Discontinued operations 59 35,925 70 37,143 Total $ 7,094 $ 43,991 $ 9,575 $ 49,130 At July 1, 2018 , the Company had gross tax effected unrecognized tax benefits of $30.5 million , of which $28.8 million , if recognized, would affect the continuing operations effective tax rate. The remaining amount, if recognized, would affect discontinued operations. The Company believes that it is reasonably possible that approximately $6.1 million of its uncertain tax positions at July 1, 2018 , including accrued interest and penalties, and net of tax benefits, may be resolved over the next twelve months as a result of lapses in applicable statutes of limitations and potential settlements. Various tax years after 2010 remain open to examination by certain jurisdictions in which the Company has significant business operations, such as Finland, Germany, Italy, Netherlands, Singapore, the United Kingdom and the United States. The tax years under examination vary by jurisdiction. During the first six months of fiscal years 2018 and 2017 , the Company recorded net discrete income tax benefit s of $1.6 million and $4.9 million , respectively. The discrete tax benefits in the first six months of fiscal year 2018 and fiscal year 2017 include recognition of excess tax benefits on stock compensation of $1.9 million and $3.4 million , respectively. On December 22, 2017, the President of the United States signed the Tax Act, which makes broad and complex changes to the U.S. Internal Revenue Code. Changes include, but are not limited to: (1) the lowering of the U.S. corporate tax rate from 35% to 21%; (2) the transition of U.S. international taxation from a worldwide tax system to a modified territorial system with a one-time transition tax on the deemed repatriation of cumulative foreign earnings as of December 31, 2017; (3) a new provision designed to tax global intangible low-taxed income (GILTI); (4) the creation of the base erosion anti-abuse tax (BEAT), which is effectively a new minimum tax; (5) the deduction for foreign-derived intangible income (FDII); (6) a new limitation on deductible interest expense; (7) the repeal of the domestic production activity deduction; and (8) limitations on the deductibility of certain executive compensation. The Company is applying the guidance in ASU 2018-05 (see Note 1, Basis of Presentation ) when accounting for the enactment date effects of the Tax Act. At July 1, 2018 , the Company has not completed the accounting for all of the tax effects of the Tax Act; however, it has made a reasonable estimate of their effects based on currently available information. As described below, the Company has made changes to certain aspects of the provision for the Tax Act. Management will continue to refine the calculations as additional guidance is available. These estimates may be affected as additional clarification and implementation guidance becomes available. These changes could be material to income tax expense. Remeasurement: The Company remeasured its future tax benefits and liabilities at the enacted tax rate of 21% and provided a provisional amount of $21.5 million during fiscal year 2017. During the six months ended July 1, 2018 , the Company recognized an additional tax expense of $1.5 million for the remeasurement of certain future tax benefits and included these adjustments as a component of provision for income tax from continuing operations. One-Time Transition Tax: The Tax Act requires the Company to pay a one-time transition tax on the unremitted earnings of foreign subsidiaries. Based on available information, the Company estimated the tax on the deemed repatriation of foreign earnings and has recorded a tax expense of $85.0 million in continuing operations at December 31, 2017. As the Company continues to refine the earnings and profit analysis and the calculations of the one-time transition tax, the measurement of this liability could be affected. As of July 1, 2018 , no changes have been made to the Company’s provisional liability associated with the one-time transition tax. GILTI, FDII, and other provisions: For fiscal year beginning in 2018, the Company is subject to several provisions of the Tax Act including computations under GILTI, FDII, and other provisions. Management has made a reasonable estimate of the impact of each provision of the Tax Act on the Company's effective tax rate for the six months ended July 1, 2018 . Management will continue to refine the provisional estimates for the computations of the GILTI, FDII, and other provisions as additional clarification and implementation guidance becomes available. Under U.S. GAAP, the Company is allowed to make an accounting policy on GILTI. The choice is either to (1) treat taxes due on future U.S. inclusions in taxable income related to GILTI as a current-period expense when incurred (the “period cost method”), or (2) factor such amounts into the measurement of deferred taxes (the “deferred method”). At July 1, 2018 , the Company is still evaluating the GILTI provisions and the analysis of future taxable income that is subject to GILTI, thus, the Company has not recorded any potential deferred tax effects related to the GILTI in the financial statements and has not made a policy decision regarding whether to record deferred taxes on GILTI or use the period cost method.

Debt

Debt	6 Months Ended
	Jul. 01, 2018
Debt Disclosure [Abstract]
Debt	Debt Senior Unsecured Revolving Credit Facility. The Company's senior unsecured revolving credit facility provides for $1.0 billion of revolving loans and has an initial maturity of August 11, 2021 . As of July 1, 2018 , undrawn letters of credit in the aggregate amount of $11.4 million were treated as issued and outstanding when calculating the borrowing availability under the senior unsecured revolving credit facility. As of July 1, 2018 , the Company had $488.6 million available for additional borrowing under the facility. The Company uses the senior unsecured revolving credit facility for general corporate purposes, which may include working capital, refinancing existing indebtedness, capital expenditures, share repurchases, acquisitions and strategic alliances. The interest rates under the senior unsecured revolving credit facility are based on the Eurocurrency rate or the base rate at the time of borrowing, plus a margin. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) an adjusted one-month Libor plus 1.00%. The Eurocurrency margin as of July 1, 2018 was 110 basis points. The weighted average Eurocurrency interest rate as of July 1, 2018 was 2.12%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 3.22%, which was the interest applicable to the borrowings outstanding under the Eurocurrency rate as of July 1, 2018 . As of July 1, 2018 , the senior unsecured revolving credit facility had outstanding borrowings of $500.0 million , and $2.9 million of unamortized debt issuance costs. As of December 31, 2017 , the senior unsecured revolving credit facility had outstanding borrowings of $625.0 million , and $3.3 million of unamortized debt issuance costs. The credit agreement for the facility contains affirmative, negative and financial covenants and events of default. The financial covenants include a debt-to-capital ratio that remains applicable for so long as the Company's debt is rated as investment grade. In the event that the Company's debt is not rated as investment grade, the debt-to-capital ratio covenant is replaced with a maximum consolidated leverage ratio covenant and a minimum consolidated interest coverage ratio covenant. Senior Unsecured Term Loan Credit Facility . The Company entered into a senior unsecured term loan credit facility on August 11, 2017 that provided for $200.0 million of term loans and had an initial maturity of twelve months from December 19, 2017, the date of the initial draw. The Company utilized the senior unsecured term loan facility for the acquisition of EUROIMMUN. The interest rates under the senior unsecured term loan credit facility were based on the Eurocurrency rate or the base rate at the time of the borrowing, plus a margin. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) an adjusted one-month Libor plus 1.00%. In April 2018, the Company paid in full the outstanding balance of $200.0 million on the Company’s senior unsecured term loan credit facility, from the proceeds of the 0.6% senior unsecured notes due in 2021 that were issued in April 2018. 5% Senior Unsecured Notes due in 2021. On October 25, 2011, the Company issued $500.0 million aggregate principal amount of senior unsecured notes due in 2021 (the “November 2021 Notes”) in a registered public offering and received $493.6 million of net proceeds from the issuance. The November 2021 Notes were issued at 99.4% of the principal amount, which resulted in a discount of $3.1 million . As of July 1, 2018 , the November 2021 Notes had an aggregate carrying value of $496.9 million , net of $1.3 million of unamortized original issue discount and $1.8 million of unamortized debt issuance costs. As of December 31, 2017 , the November 2021 Notes had an aggregate carrying value of $496.6 million , net of $1.4 million of unamortized original issue discount and $2.0 million of unamortized debt issuance costs. The November 2021 Notes mature in November 2021 and bear interest at an annual rate of 5% . Interest on the November 2021 Notes is payable semi-annually on May 15th and November 15th each year. Prior to August 15, 2021 (three months prior to their maturity date), the Company may redeem the November 2021 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the November 2021 Notes to be redeemed, plus accrued and unpaid interest, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the November 2021 Notes being redeemed, discounted on a semi-annual basis, at the Treasury Rate plus 45 basis points, plus accrued and unpaid interest. At any time on or after August 15, 2021 (three months prior to their maturity date), the Company may redeem the November 2021 Notes, at its option, at a redemption price equal to 100% of the principal amount of the November 2021 Notes to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the November 2021 Notes) and a contemporaneous downgrade of the November 2021 Notes below investment grade, each holder of November 2021 Notes will have the right to require the Company to repurchase such holder's November 2021 Notes for 101% of their principal amount, plus accrued and unpaid interest. 1.875% Senior Unsecured Notes due 2026. On July 19, 2016, the Company issued €500.0 million aggregate principal amount of senior unsecured notes due in 2026 (the “2026 Notes”) in a registered public offering and received approximately €492.3 million of net proceeds from the issuance. The 2026 Notes were issued at 99.118% of the principal amount, which resulted in a discount of €4.4 million . The 2026 Notes mature in July 2026 and bear interest at an annual rate of 1.875% . Interest on the 2026 Notes is payable annually on July 19th each year. The proceeds from the 2026 Notes were used to pay in full the outstanding balance of the Company's previous senior unsecured revolving credit facility. As of July 1, 2018 , the 2026 Notes had an aggregate carrying value of $575.1 million , net of $4.3 million of unamortized original issue discount and $4.0 million of unamortized debt issuance costs. As of December 31, 2017 , the 2026 Notes had an aggregate carrying value of $591.7 million , net of $4.7 million of unamortized original issue discount and $4.3 million of unamortized debt issuance costs. Prior to April 19, 2026 (three months prior to their maturity date), the Company may redeem the 2026 Notes in whole at any time or in part from time to time, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2026 Notes to be redeemed, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2026 Notes being redeemed, discounted on an annual basis, at the applicable Comparable Government Bond Rate (as defined in the indenture governing the 2026 Notes) plus 35 basis points; plus, in each case, accrued and unpaid interest. In addition, at any time on or after April 19, 2026 (three months prior to their maturity date), the Company may redeem the 2026 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2026 Notes due to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2026 Notes) and a contemporaneous downgrade of the 2026 Notes below investment grade, the Company will, in certain circumstances, make an offer to purchase the 2026 Notes at a price equal to 101% of their principal amount plus any accrued and unpaid interest. 0.6% Senior Unsecured Notes due in 2021. On April 11, 2018, the Company issued €300.0 million aggregate principal amount of senior unsecured notes due in 2021 (the “April 2021 Notes”) in a registered public offering and received approximately €298.7 million of net proceeds from the issuance. The April 2021 Notes were issued at 99.95% of the principal amount, which resulted in a discount of €0.2 million . As of July 1, 2018 , the April 2021 Notes had an aggregate carrying value of $347.2 million , net of $0.2 million of unamortized original issue discount and $2.7 million of unamortized debt issuance costs. The April 2021 Notes mature in April 2021 and bear interest at an annual rate of 0.6% . Interest on the April 2021 Notes is payable annually on April 9th each year. The proceeds from the April 2021 Notes were used to pay in full the outstanding balance of the Company’s senior unsecured term loan credit facility, and a portion of the outstanding senior unsecured revolving credit facility, and in each case the borrowings were incurred to pay a portion of the purchase price for the Company's acquisition of EUROIMMUM, which closed in December 19, 2017. Prior to the maturity date of the April 2021 Notes, the Company may redeem them in whole at any time or in part from time to time, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the April 2021 Notes to be redeemed, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the April 2021 Notes being redeemed, discounted on an annual basis, at the applicable Comparable Government Bond Rate (as defined in the indenture governing the April 2021 Notes) plus 15 basis points; plus, in each case, accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the April 2021 Notes) and a contemporaneous downgrade of the April 2021 Notes below investment grade, the Company will, in certain circumstances, make an offer to purchase the April 2021 Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest. Other Debt Facilities. The Company's other debt facilities include Euro-denominated bank loans with an aggregate carrying value of $46.4 million (or €39.8 million ) and $57.2 million (or €47.6 million ) as of July 1, 2018 and December 31, 2017 , respectively. These bank loans are primarily utilized for financing fixed assets and are repaid in monthly or quarterly installments with maturity dates extending to 2031. The bank loans in the aggregate amount of $42.8 million bear fixed interest rates between 1.1% and 7.9% and bank loans in the aggregate amount of $3.6 million bear variable interest rates based on the Euribor rate plus a margin between 1.3% and 1.5% . An aggregate amount of $5.6 million of the bank loans are secured by mortgages on real property and the remaining $40.8 million are unsecured. Certain credit agreements for the unsecured bank loans include financial covenants which are based on an equity ratio or an equity ratio and minimum interest coverage ratio. In addition, the Company has other unsecured revolving credit facilities and a secured bank loan in the amount of $2.2 million and $0.3 million , respectively, as of July 1, 2018 . The unsecured revolving debt facilities bear fixed interest rates between 0.05% and 1.95% and will mature in 2018. The secured bank loan of $0.3 million bears a fixed annual interest rate of 1.95% and is repaid in monthly installments until 2027. Financing Lease Obligations. In fiscal year 2012, the Company entered into agreements with the lessors of certain buildings that the Company is currently occupying and leasing to expand those buildings. The Company provided a portion of the funds needed for the construction of the additions to the buildings, and as a result the Company was considered the owner of the buildings during the construction period. At the end of the construction period, the Company was not reimbursed by the lessors for all of the construction costs. The Company is therefore deemed to have continuing involvement and the leases qualify as financing leases under sale-leaseback accounting guidance, representing debt obligations for the Company and non-cash investing and financing activities. As a result, the Company capitalized $29.3 million in property, plant and equipment, net, representing the fair value of the buildings with a corresponding increase to debt. The Company has also capitalized $11.5 million in additional construction costs necessary to complete the renovations to the buildings, which were funded by the lessors, with a corresponding increase to debt. At July 1, 2018 , the Company had $35.3 million recorded for these financing lease obligations, of which $1.5 million was recorded as short-term debt and $33.8 million was recorded as long-term debt. At December 31, 2017 , the Company had $35.9 million recorded for these financing lease obligations, of which $1.4 million was recorded as short-term debt and $34.5 million was recorded as long-term debt. The buildings are being depreciated on a straight-line basis over the terms of the leases to their estimated residual values, which will equal the remaining financing obligation at the end of the lease term. At the end of the lease term, the remaining balances in property, plant and equipment, net and debt will be reversed against each other.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jul. 01, 2018
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations: Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Number of common shares—basic 110,477 109,894 110,386 109,681 Effect of dilutive securities: Stock options 786 668 824 636 Restricted stock awards 189 200 181 167 Number of common shares—diluted 111,452 110,762 111,391 110,484 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 346 457 339 558 Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future.

Industry Segment Information

Industry Segment Information	6 Months Ended
	Jul. 01, 2018
Segment Reporting [Abstract]
Industry Segment Information	Industry Segment Information The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1 to the audited consolidated financial statements in the 2017 Form 10-K. The principal products and services of the Company's two operating segments are: • Discovery & Analytical Solutions . Provides products and services targeted towards the life sciences and applied markets. • Diagnostics . Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the reproductive health, emerging market diagnostics and applied genomics markets. The Diagnostics segment serves the diagnostics market. The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments. Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below: Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Discovery & Analytical Solutions Product revenue $ 263,325 $ 227,290 $ 501,020 $ 442,450 Service revenue 167,303 155,838 326,133 302,438 Total revenue 430,628 383,128 827,153 744,888 Operating income from continuing operations 64,665 51,124 100,862 81,346 Diagnostics Product revenue 232,283 127,711 442,196 246,265 Service revenue 40,451 36,123 77,985 69,924 Total revenue 272,734 163,834 520,181 316,189 Operating income from continuing operations 38,780 36,947 57,174 69,663 Corporate Operating loss from continuing operations (15,381 ) (13,888 ) (30,037 ) (27,015 ) Continuing Operations Product revenue 495,608 355,001 943,216 688,715 Service revenue 207,754 191,961 404,118 372,362 Total revenue 703,362 546,962 1,347,334 1,061,077 Operating income from continuing operations 88,064 74,183 127,999 123,994 Interest and other expense, net (see Note 7) 16,356 3,391 27,786 13,219 Income from continuing operations before income taxes $ 71,708 $ 70,792 $ 100,213 $ 110,775

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jul. 01, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity Comprehensive Income: The components of accumulated other comprehensive loss consisted of the following: July 1, December 31, (In thousands) Foreign currency translation adjustments $ (130,675 ) $ (46,582 ) Unrecognized prior service costs, net of income taxes 322 322 Unrealized net losses on securities, net of income taxes (213 ) (258 ) Accumulated other comprehensive loss $ (130,566 ) $ (46,518 ) Stock Repurchases: On July 27, 2016, the Board of Directors (the "Board") authorized the Company to repurchase up to 8.0 million shares of common stock under a stock repurchase program (the "Repurchase Program") that was scheduled to expire on July 26, 2018 unless terminated earlier by the Board. During the six months ended July 1, 2018 , the Company had no stock repurchases under the Repurchase Program. As of July 1, 2018 , 8.0 million shares remained available for repurchase under the Repurchase Program. On July 23, 2018, the Board authorized the Company to immediately terminate the Repurchase Program and further authorized the Company to repurchase shares of common stock for an aggregate amount up to $250.0 million under a new stock repurchase program (the "New Repurchase Program"). The New Repurchase Program will expire on July 23, 2020 unless terminated earlier by the Board and may be suspended or discontinued at any time. In addition, the Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company's equity incentive plans. During the three months ended July 1, 2018 , the Company repurchased 1,250 shares of common stock for this purpose at an aggregate cost of $0.1 million . During the six months ended July 1, 2018 , the Company repurchased 59,699 shares of common stock for this purpose at an aggregate cost of $4.6 million . The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value. Dividends: The Board declared a regular quarterly cash dividend of $0.07 per share for the first two quarters of fiscal year 2018 and in each quarter of fiscal year 2017 . At July 1, 2018 , the Company has accrued $7.7 million for dividends declared on April 26, 2018 for the second quarter of fiscal year 2018 that will be payable on August 10, 2018 . On July 23, 2018 , the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the third quarter of fiscal year 2018 that will be payable on November 10, 2018 . In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Stock Plans

Stock Plans	6 Months Ended
	Jul. 01, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Plans	Stock Plans In addition to the Company's Employee Stock Purchase Plan, the Company utilizes one stock-based compensation plan, the 2009 Incentive Plan (the “2009 Plan”). Under the 2009 Plan, 10.0 million shares of the Company's common stock are authorized for stock option grants, restricted stock awards, performance restricted stock units, performance units and stock awards as part of the Company’s compensation programs. In addition to shares of the Company’s common stock originally authorized for issuance under the 2009 Plan, the 2009 Plan includes shares of the Company’s common stock previously granted under the Amended and Restated 2001 Incentive Plan and the 2005 Incentive Plan that were canceled or forfeited without the shares being issued. The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock option grants, restricted stock awards, performance restricted stock units, performance units and stock awards, included in the Company’s condensed consolidated statements of operations for the three and six months ended July 1, 2018 and July 2, 2017 : Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Cost of revenue $ 358 $ 281 $ 663 $ 541 Research and development expenses 386 377 694 704 Selling, general and administrative expenses 6,072 6,183 10,791 10,522 Total stock-based compensation expense $ 6,816 $ 6,841 $ 12,148 $ 11,767 The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $1.6 million and $4.5 million for the three and six months ended July 1, 2018 , respectively. The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $5.1 million and $8.0 million for the three and six months ended July 2, 2017 , respectively. Stock-based compensation costs capitalized as part of inventory were $0.4 million as of each of July 1, 2018 and July 2, 2017 . Stock Options : The fair value of each option grant is estimated using the Black-Scholes option pricing model. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows: Three and Six Months Ended July 1, July 2, Risk-free interest rate 2.9 % 1.8 % Expected dividend yield 0.4 % 0.5 % Expected term 5 years 5 years Expected stock volatility 20.7 % 22.4 % The following table summarizes stock option activity for the six months ended July 1, 2018 : Number of Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term Total Intrinsic Value (In thousands) (In years) (In millions) Outstanding at December 31, 2017 2,154 $ 42.77 Granted 342 77.61 Exercised (194 ) 42.98 Forfeited (10 ) 59.61 Outstanding at July 1, 2018 2,292 $ 47.88 3.9 $ 58.1 Exercisable at July 1, 2018 1,464 $ 40.05 2.9 $ 48.6 The weighted-average per-share grant-date fair value of options granted during the three and six months ended July 1, 2018 was $17.30 and $17.49 , respectively. The weighted-average per-share grant-date fair value of options granted during the three and six months ended July 2, 2017 was $13.27 and $11.74 , respectively. The total intrinsic value of options exercised during the three and six months ended July 1, 2018 was $0.7 million and $6.4 million , respectively. The total intrinsic value of options exercised during the three and six months ended July 2, 2017 was $9.1 million and $12.2 million , respectively. Cash received from option exercises for the six months ended July 1, 2018 and July 2, 2017 was $8.3 million and $13.2 million , respectively. The total compensation expense recognized related to the Company’s outstanding options was $1.3 million and $2.6 million for the three and six months ended July 1, 2018 , respectively, and $1.2 million and $2.4 million for the three and six months ended July 2, 2017 , respectively. There was $9.2 million of total unrecognized compensation cost related to nonvested stock options granted as of July 1, 2018 . This cost is expected to be recognized over a weighted-average period of 2.1 years. Restricted Stock Awards : The following table summarizes restricted stock award activity for the six months ended July 1, 2018 : Number of Shares Weighted- Average Grant- Date Fair Value (In thousands) Nonvested at December 31, 2017 496 $ 50.30 Granted 194 75.37 Vested (181 ) 49.54 Forfeited (12 ) 55.62 Nonvested at July 1, 2018 497 $ 60.26 The fair value of restricted stock awards vested during the three and six months ended July 1, 2018 was $0.7 million and $9.0 million , respectively. The fair value of restricted stock awards vested during the three and six months ended July 2, 2017 was $1.5 million and $9.3 million , respectively. The total compensation expense recognized related to the Company’s outstanding restricted stock awards was $3.2 million and $5.6 million for the three and six months ended July 1, 2018 , respectively, and $3.0 million and $5.4 million for the three and six months ended July 2, 2017 , respectively. As of July 1, 2018 , there was $21.6 million of total unrecognized compensation cost related to nonvested restricted stock awards. This cost is expected to be recognized over a weighted-average period of 1.7 years. Performance Restricted Stock Units: As part of the Company's executive compensation program, the Company granted 39,133 performance restricted stock units during the six months ended July 1, 2018 that will vest based on performance of the Company. The weighted-average per-share grant date fair value of performance restricted stock units granted during the six months ended July 1, 2018 was $80.31 . During the six months ended July 1, 2018 , no performance restricted stock units were forfeited. As of July 1, 2018 , there were 93,470 performance restricted stock units outstanding. The total compensation expense recognized related to the performance restricted stock units was $0.5 million and $0.9 million for the three and six months ended July 1, 2018 , respectively, and $0.2 million and $0.5 million for the three and six months ended July 2, 2017 , respectively. Performance Units : As part of the Company's executive compensation program, the Company granted 37,281 performance units during the six months ended July 1, 2018 . The weighted-average per-share grant-date fair value of performance units granted during the six months ended July 1, 2018 was $73.23 . During the six months ended July 1, 2018 , no performance units were forfeited. As of July 1, 2018 , there were 201,762 performance units outstanding and subject to forfeiture, with a corresponding liability of $8.6 million recorded in accrued expenses and other current liabilities. The total compensation expense recognized related to performance units was $1.0 million and $2.3 million for the three and six months ended July 1, 2018 , respectively, and $1.7 million and $2.8 million for the three and six months ended July 2, 2017 , respectively. Stock Awards : The Company’s stock award program provides an annual equity award to non-employee directors. The Company granted 1,386 shares to each non-employee member of the Board during the six months ended July 1, 2018 . The weighted-average per-share grant-date fair value of the stock awards granted during the six months ended July 1, 2018 was $72.17 . The total compensation expense recognized related to the stock awards was $0.8 million and $0.7 million for the six months ended July 1, 2018 and July 2, 2017 , respectively. Employee Stock Purchase Plan : During the six months ended July 1, 2018 , the Company issued 21,321 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $69.57 per share. During the six months ended July 2, 2017 , the Company issued 18,483 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $64.73 per share. At July 1, 2018 , an aggregate of 0.8 million shares of the Company’s common stock remained available for sale to employees out of the 5.0 million shares authorized by shareholders for issuance under this plan.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	6 Months Ended
	Jul. 01, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill . The Company performed its annual impairment testing for its reporting units as of January 1, 2018 , its annual impairment testing date for fiscal year 2018 . The Company concluded that there was no goodwill impairment, and the fair value exceeded the carrying value by more than 20.0% for each reporting unit, except for the Company's Informatics reporting unit which had a fair value that was less than 20% but more than 10% of its carrying value. The range of the long-term terminal growth rates for the Company’s reporting units was 3.0% to 5.00% for the fiscal year 2018 impairment analysis. The range for the discount rates for the reporting units was 9.0% to 15.0% . Keeping all other variables constant, a 10.0% change in any one of these input assumptions for the various reporting units, except for the Informatics reporting unit, would still allow the Company to conclude that there was no impairment of goodwill. As of January 1, 2018 , the Company's Informatics reporting unit, which had a goodwill balance of $217.2 million , was at increased risk of an impairment charge given its ongoing weakness due to a highly competitive industry. Despite the increased risk associated with this reporting unit, the Company does not currently expect a significant change in the key estimates or assumptions driving the fair value of this reporting unit that would lead to a material impairment charge. The Company has consistently employed the income approach to estimate the current fair value when testing for impairment of goodwill. A number of significant assumptions and estimates are involved in the application of the income approach to forecast operating cash flows, including markets and market share, sales volumes and prices, costs to produce, tax rates, capital spending, discount rates and working capital changes. Cash flow forecasts are based on approved business unit operating plans for the early years’ cash flows and historical relationships in later years. The income approach is sensitive to changes in long-term terminal growth rates and the discount rates. The long-term terminal growth rates are consistent with the Company’s historical long-term terminal growth rates, as the current economic trends are not expected to affect the long-term terminal growth rates of the Company. The Company corroborates the income approach with a market approach. The Company has consistently employed the relief from royalty model to estimate the current fair value when testing for impairment of non-amortizing intangible assets. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized . In addition, the Company evaluates the remaining useful lives of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful lives and accounted for in the same manner as other intangible assets that are subject to amortization. The Company performed its annual impairment testing as of January 1, 2018 , and concluded that there was no impairment of non-amortizing intangible assets. An assessment of the recoverability of amortizing intangible assets takes place when events have occurred that may give rise to an impairment. No such events occurred during the first six months of fiscal year 2018 . The changes in the carrying amount of goodwill for the six months ended July 1, 2018 were as follows: Discovery & Analytical Solutions Diagnostics Consolidated (In thousands) Balance at December 31, 2017 $ 1,344,235 $ 1,657,963 $ 3,002,198 Foreign currency translation (22,053 ) (26,648 ) (48,701 ) Acquisitions and other 10,191 (22,863 ) (12,672 ) Balance at July 1, 2018 $ 1,332,373 $ 1,608,452 $ 2,940,825 Identifiable intangible asset balances at July 1, 2018 and December 31, 2017 by category were as follows: July 1, December 31, (In thousands) Patents $ 39,953 $ 39,959 Less: Accumulated amortization (36,389 ) (35,085 ) Net patents 3,564 4,874 Trade names and trademarks 79,586 80,974 Less: Accumulated amortization (31,400 ) (28,250 ) Net trade names and trademarks 48,186 52,724 Licenses 51,720 53,300 Less: Accumulated amortization (44,062 ) (42,635 ) Net licenses 7,658 10,665 Core technology 478,499 471,740 Less: Accumulated amortization (263,080 ) (244,916 ) Net core technology 215,419 226,824 Customer relationships 1,126,608 1,141,511 Less: Accumulated amortization (276,368 ) (242,840 ) Net customer relationships 850,240 898,671 IPR&D 81,152 88,025 Less: Accumulated amortization (5,936 ) (5,427 ) Net IPR&D 75,216 82,598 Net amortizable intangible assets 1,200,283 1,276,356 Non-amortizing intangible asset: Trade name 70,584 70,584 Total $ 1,270,867 $ 1,346,940 Total amortization expense related to definite-lived intangible assets was $32.5 million and $65.4 million for the three and six months ended July 1, 2018 , respectively, and $17.5 million and $34.6 million for the three and six months ended July 2, 2017 , respectively. Estimated amortization expense related to definite-lived intangible assets for each of the next five years is $68.3 million for the remainder of fiscal year 2018 , $144.5 million for fiscal year 2019 , $146.9 million for fiscal year 2020 , $131.6 million for fiscal year 2021 , and $119.6 million for fiscal year 2022 .

Warranty Reserves

Warranty Reserves	6 Months Ended
	Jul. 01, 2018
Product Warranties Disclosures [Abstract]
Warranty Reserves	Warranty Reserves The Company provides warranty protection for certain products usually for a period of one year beyond the date of sale. The majority of costs associated with warranty obligations include the replacement of parts and the time for service personnel to respond to repair and replacement requests. A warranty reserve is recorded based upon historical results, supplemented by management’s expectations of future costs. Warranty reserves are included in “Accrued expenses and other current liabilities” on the condensed consolidated balance sheets. A summary of warranty reserve activity for the three and six months ended July 1, 2018 and July 2, 2017 is as follows: Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Balance at beginning of period $ 8,786 $ 8,937 $ 9,050 $ 9,012 Provision charged to income 3,515 3,391 6,685 6,380 Payments (3,490 ) (3,412 ) (6,967 ) (7,137 ) Adjustments to previously provided warranties, net 446 (24 ) 336 515 Foreign currency translation and acquisitions (314 ) 196 (161 ) 318 Balance at end of period $ 8,943 $ 9,088 $ 8,943 $ 9,088

Employee Benefit Plans

Employee Benefit Plans	6 Months Ended
	Jul. 01, 2018
Retirement Benefits [Abstract]
Employee Benefit Plans	Employee Postretirement Benefit Plans The following table summarizes the components of net periodic pension credit for the Company’s various defined benefit employee pension and postretirement plans for the three and six months ended July 1, 2018 and July 2, 2017 : Defined Benefit Pension Benefits Postretirement Medical Benefits Three Months Ended July 1, July 2, July 1, July 2, (In thousands) Service and administrative costs $ 1,712 $ 1,222 $ 26 $ 23 Interest cost 4,057 4,133 30 31 Expected return on plan assets (7,310 ) (6,541 ) (313 ) (278 ) Amortization of prior service costs (41 ) (48 ) — — Net periodic pension credit $ (1,582 ) $ (1,234 ) $ (257 ) $ (224 ) Defined Benefit Pension Benefits Postretirement Medical Benefits Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Service and administrative costs $ 3,468 $ 2,436 $ 53 $ 46 Interest cost 8,161 8,260 60 62 Expected return on plan assets (14,656 ) (13,041 ) (627 ) (557 ) Amortization of prior service costs (82 ) (95 ) — — Net periodic benefit credit $ (3,109 ) $ (2,440 ) $ (514 ) $ (449 ) During the six months ended July 1, 2018 and July 2, 2017 , the Company contributed $4.4 million and $4.1 million , respectively, in the aggregate, to pension plans outside of the United States. During the six months ended July 1, 2018 , the Company contributed $15.0 million to its defined benefit pension plan in the United States for the plan year 2017. The Company recognizes actuarial gains and losses, unless an interim remeasurement is required, in the fourth quarter of the year in which the gains and losses occur, in accordance with the Company's accounting method for defined benefit pension plans and other postretirement benefits as described in Note 1 of the Company's audited consolidated financial statements and notes included in its 2017 Form 10-K. Such adjustments for gains and losses are primarily driven by events and circumstances beyond the Company's control, including changes in interest rates, the performance of the financial markets and mortality assumptions. As discussed in Note 1, Basis of Presentation, the Company adopted ASU 2017-17 on January 1, 2018. Actuarial gains and losses are now recognized in the line item "Interest and other expense, net" in the condensed consolidated statement of operations. Actuarial gains and losses were presented within operating income prior to the adoption. As such, prior year amounts, including other components of periodic pension cost, have been reclassified to "Interest and other expense, net" in the condensed consolidated statement of operations due to the retrospective adoption of ASU 2017-07.

Derivatives And Hedging Activit

Derivatives And Hedging Activities	6 Months Ended
	Jul. 01, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Hedging Activities	Derivatives and Hedging Activities The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 70% of the Company’s business is conducted outside of the United States, generally in foreign currencies. As a result, fluctuations in foreign currency exchange rates can increase the costs of financing, investing and operating the business. In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s condensed consolidated balance sheets. The unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from operating activities within the Company’s condensed consolidated statement of cash flows. Principal hedged currencies include the British Pound, Euro, Swedish Krona, Japanese Yen and Singapore Dollar. The Company held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling $147.6 million , $212.1 million and $128.6 million at July 1, 2018 , December 31, 2017 and July 2, 2017 , respectively, and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on these foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during each of the six months ended July 1, 2018 and July 2, 2017 . In addition, in connection with certain intercompany loan agreements utilized to finance its acquisitions and stock repurchase program, the Company enters into forward foreign exchange contracts intended to hedge movements in foreign exchange rates prior to settlement of such intercompany loans denominated in foreign currencies. The Company records these hedges at fair value on the Company’s condensed consolidated balance sheets. The unrealized gains and losses on these hedges, as well as the gains and losses associated with the remeasurement of the intercompany loans, are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from financing activities within the Company’s condensed consolidated statement of cash flows. The outstanding forward exchange contracts designated as economic hedges, which were intended to hedge movements in foreign exchange rates prior to the settlement of certain intercompany loan agreements, included combined Euro notional amounts of €49.7 million and combined U.S. Dollar notional amounts of $50.8 million as of July 1, 2018 , combined Euro notional amounts of €57.2 million and combined U.S. Dollar notional amounts of $1.3 billion as of December 31, 2017 , and combined Euro notional amounts of €23.5 million and combined U.S. Dollar notional amounts of $133.3 million as of July 2, 2017 . The net gains and losses on these derivatives, combined with the gains and losses on the remeasurement of the hedged intercompany loans were not material for each of the three and six months ended July 1, 2018 and July 2, 2017 . The Company paid $32.7 million and $4.3 million during the six months ended July 1, 2018 and July 2, 2017 , respectively, from the settlement of these hedges. In April 2018, the Company entered into a series of foreign currency forward contracts with a notional amount of €298.7 million to hedge its investments in certain foreign subsidiaries. Realized and unrealized translation adjustments from these hedges were included in the foreign currency translation component of accumulated other comprehensive income ("AOCI"), which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. The foreign currency forward contracts were settled during the second quarter of 2018 and the Company recorded a net realized foreign exchange loss in AOCI of $2.6 million for the three and six months ended July 1, 2018 . During fiscal year 2016, the Company designated the 2026 Notes to hedge its investments in certain foreign subsidiaries. In January 2018, the Company removed the hedging relationship of its 2026 Notes and investments in certain foreign subsidiaries and recognized $2.1 million of unrealized foreign exchange gain in AOCI. In April 2018, the Company designated a portion of the 2026 Notes to hedge its investments in certain foreign subsidiaries. Unrealized translation adjustments from a portion of the 2026 Notes were included in the foreign currency translation component of AOCI, which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of July 1, 2018 , the total notional amount of the 2026 Notes that was designated to hedge investments in foreign subsidiaries was €135.6 million . The unrealized foreign exchange gain recorded in AOCI related to the net investment hedge was $4.8 million and $6.9 million for the three and six months ended July 1, 2018 , respectively. In April 2018, the Company designated the April 2021 Notes with a notional amount of €298.7 million to hedge its investments in certain foreign subsidiaries. Unrealized translation adjustments from the April 2021 Notes were included in the foreign currency translation component of AOCI, which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of July 1, 2018 , the total notional amount of the April 2021 Notes that was designated to hedge investments in foreign subsidiaries was €298.7 million . The unrealized foreign exchange gain recorded in AOCI related to the net investment hedge was $20.8 million for the three and six months ended July 1, 2018 . The Company does no t expect any material net pre-tax gains or losses to be reclassified from accumulated other comprehensive loss into interest and other expense, net within the next twelve months.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jul. 01, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of July 1, 2018 . The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during the six months ended July 1, 2018 . The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition-related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value. Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of July 1, 2018 and December 31, 2017 classified in one of the three classifications described above: Fair Value Measurements at July 1, 2018 Using: Total Carrying Value at July 1, 2018 Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable (Level 3) (In thousands) Marketable securities $ 2,271 $ 2,271 $ — $ — Foreign exchange derivative assets 3,367 — 3,367 — Foreign exchange derivative liabilities (535 ) — (535 ) — Contingent consideration (74,093 ) — — (74,093 ) Fair Value Measurements at December 31, 2017 Using: Total Carrying Value at December 31, 2017 Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 2,208 $ 2,208 $ — $ — Foreign exchange derivative assets 1,431 — 1,431 — Foreign exchange derivative liabilities (23,638 ) — (23,638 ) — Contingent consideration (65,328 ) — — (65,328 ) Level 1 and Level 2 Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities. Marketable securities: Include equity and fixed-income securities measured at fair value using the quoted market prices in active markets at the reporting date. Foreign exchange derivative assets and liabilities: Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company's condensed consolidated balance sheet on a net basis and are recorded in other assets. As of both July 1, 2018 and December 31, 2017 , none of the master netting arrangements involved collateral. Level 3 Valuation Techniques: The Company’s Level 3 liabilities are comprised of contingent consideration related to acquisitions. For liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 liabilities. Contingent consideration: Contingent consideration is measured at fair value at the acquisition date using projected milestone dates, discount rates, probabilities of success and projected revenues (for revenue-based considerations). Projected risk-adjusted contingent payments are discounted back to the current period using a discounted cash flow model. During fiscal year 2015, the Company acquired certain assets and assumed certain liabilities from Vanadis Diagnostics AB. Under the terms of the acquisition, the initial purchase consideration was $32.0 million , net of cash and the Company will be obligated to make potential future milestone payments, based on completion of a proof of concept, regulatory approvals and product sales, of up to $93.0 million ranging from 2016 to 2019. The fair value of the contingent consideration as of the acquisition date was estimated at $56.9 million . During the second quarter of fiscal year 2018 , the Company updated the fair value of the contingent consideration and recorded a liability of $72.4 million as of July 1, 2018 . The key assumptions used to determine the fair value of the contingent consideration as of July 1, 2018 included projected milestone dates of 2018 to 2019 , discount rates ranging from 3.1% to 9.1% , conditional probabilities of success of each individual milestone ranging from 90% to 100% and cumulative probabilities of success for each individual milestone ranging from 73.1% to 100% . A significant delay in the product development (including projected regulatory milestone) achievement date in isolation could result in a significantly lower fair value measurement; a significant acceleration in the product development (including projected regulatory milestone) achievement date in isolation would not have a material impact on the fair value measurement; a significant change in the discount rate in isolation would not have a material impact on the fair value measurement; and a significant change in the probabilities of success in isolation could result in a significant change in fair value measurement. During the second quarter of fiscal year 2018 , the Company recorded a contingent consideration obligation relating to its acquisition of SSI with an estimated fair value of $1.7 million . The fair values of contingent consideration are calculated on a quarterly basis based on a collaborative effort of the Company’s regulatory, research and development, operations, finance and accounting groups, as appropriate. Potential valuation adjustments are made as additional information becomes available, including the progress towards achieving proof of concept, regulatory approvals and revenue targets as compared to initial projections, the impact of market competition and market landscape shifts from non-invasive prenatal testing products, with the impact of such adjustments being recorded in the Company's consolidated statements of operations. As of July 1, 2018 , the Company may have to pay contingent consideration related to acquisitions with open contingency periods of up to $85.0 million . The expected maximum earnout period for the acquisitions with open contingency periods does not exceed 1.3 years from July 1, 2018 , and the remaining weighted average expected earnout period at July 1, 2018 was 0.5 years . A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Balance at beginning of period $ (65,445 ) $ (63,978 ) $ (65,328 ) $ (63,201 ) Additions (1,700 ) — (1,700 ) — Amounts paid and foreign currency translation — — — 34 Change in fair value (included within selling, general and administrative expenses) (6,948 ) (98 ) (7,065 ) (909 ) Balance at end of period $ (74,093 ) $ (64,076 ) $ (74,093 ) $ (64,076 ) The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1. As of July 1, 2018 , the Company’s senior unsecured revolving credit facility, which provides for $1.0 billion of revolving loans, had a carrying value of $497.1 million , net of $2.9 million of unamortized debt issuance costs. As of December 31, 2017 , the Company’s senior unsecured revolving credit facility had a carrying value of $621.7 million , net of $3.3 million of unamortized debt issuance costs. The interest rate on the Company’s senior unsecured revolving credit facility is reset at least monthly to correspond to variable rates that reflect currently available terms and conditions for similar debt. The Company had no change in credit standing during the first six months of fiscal year 2018 . Consequently, the carrying value approximates fair value and were classified as Level 2. The Company's November 2021 Notes, with a face value of $500.0 million , had an aggregate carrying value of $496.9 million , net of $1.3 million of unamortized original issue discount and $1.8 million of unamortized debt issuance costs as of July 1, 2018 . The November 2021 Notes had an aggregate carrying value of $496.6 million , net of $1.4 million of unamortized original issue discount and $2.0 million of unamortized debt issuance costs as of December 31, 2017 . The November 2021 Notes had a fair value of $521.0 million and $536.6 million as of July 1, 2018 and December 31, 2017 , respectively. The fair value of the November 2021 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's 2026 Notes, with a face value of €500.0 million , had an aggregate carrying value of $575.1 million , net of $4.3 million of unamortized original issue discount and $4.0 million of unamortized debt issuance costs as of July 1, 2018 . The 2026 Notes had an aggregate carrying value of $591.7 million , net of $4.7 million of unamortized original issue discount and $4.3 million of unamortized debt issuance costs as of December 31, 2017 . The 2026 Notes had a fair value of €506.6 million and €508.9 million as of July 1, 2018 and December 31, 2017 , respectively. The fair value of the 2026 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's April 2021 Notes, with a face value of €300.0 million , had an aggregate carrying value of $347.2 million , net of $0.2 million of unamortized original issue discount and $2.7 million of unamortized debt issuance costs as of July 1, 2018 . The April 2021 Notes had a fair value of €301.9 million as of July 1, 2018 . The fair value of the April 2021 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's financing lease obligations had an aggregate carrying value of $35.3 million and $35.9 million as of July 1, 2018 and December 31, 2017 , respectively. The carrying values of the Company's financing lease obligations approximated their fair value as there has been minimal change in the Company's incremental borrowing rate. As of July 1, 2018 , the November 2021 Notes, 2026 Notes, April 2021 Notes and financing lease obligations were classified as Level 2. The Company’s other debt facilities that were assumed from the EUROIMMUN acquisition had an aggregate carrying value of $48.9 million and $60.2 million as of July 1, 2018 and December 31, 2017 , respectively. The bank loans in the aggregate amount of $45.3 million bear fixed interest rates between 0.05% and 7.9% and bank loans in the aggregate amount of $3.6 million bear variable interest rates based on the Euribor rate plus a margin between 1.3% and 1.5% . The Company had no change in credit standing during the first six months of fiscal year 2018 . Consequently, the carrying value approximates fair value and were classified as Level 2. As of July 1, 2018 , there has not been any significant impact to the fair value of the Company’s derivative liabilities due to credit risk. Similarly, there has not been any significant adverse impact to the Company’s derivative assets based on the evaluation of its counterparties’ credit risks.

Contingencies

Contingencies	6 Months Ended
	Jul. 01, 2018
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company’s responsibility is established and when the cost can be reasonably estimated. The Company has accrued $9.1 million and $9.4 million as of July 1, 2018 and December 31, 2017 , respectively, which represents its management’s estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims. These amounts were included in accrued expenses and other current liabilities. The Company's environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s condensed consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the condensed consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded. The Company is subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at this time, the total cost of resolving these contingencies at July 1, 2018 would not have a material adverse effect on the Company’s condensed consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company.

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Jul. 01, 2018
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted and Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In June 2018, the FASB issued Accounting Standards Update No. 2018-07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting ("ASU 2018-07") which supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-employees , and expands the scope of Topic 718 (which currently only includes share-based payments to employees) to also include share-based payments issued to non-employees for goods and services, except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards, except for financing transactions, or awards issued to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers ("Topic 606"). The provisions of this guidance are to be applied using a modified retrospective approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified non-employee awards that have not been settled as of the adoption date and (2) equity-classified non-employee awards for which a measurement date has not been established. ASU 2018-07 is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606. The Company early adopted the provisions of this guidance effective July 2, 2018. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flow. In March 2018, the FASB Issued Accounting Standards Update No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("ASU 2018-05"). ASU 2018-05 was issued to incorporate into Topic 740 recent SEC guidance related to the income tax accounting implications of the Tax Cut and Jobs Act (the "Tax Act"). The SEC issued Staff Accounting Bulletin No. 118 ("SAB 118") to address concerns about reporting entities’ ability to timely comply with the accounting requirements to recognize all of the effects of the Tax Act in the period of enactment. SAB 118 permits companies to disclose that some or all of the income tax effects from the Tax Act are incomplete by the due date of the financial statements, and if possible, disclose a reasonable estimate of such tax effects. ASU 2018-05 is effective immediately. The Company is applying the guidance in ASU 2018-05 when accounting for the enactment date effects of the Tax Act. At July 1, 2018, the Company has not completed the accounting for all of the tax effects of the Tax Act; however, it has made a reasonable estimate of their effects based on currently available information. Management will continue to refine the calculations as additional guidance is available. These estimates may be affected as additional clarification and implementation guidance becomes available. These changes could be material to income tax expense (see Note 9, Income Taxes for further disclosures). In February 2018, the FASB Issued Accounting Standards Update No. 2018-03, Technical Corrections and Improvements to Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2018-03") . ASU 2018-03 was issued to clarify certain aspects of guidance concerning the recognition of financial assets and liabilities established in Accounting Standards Update No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"). This includes treatment for discontinuations and adjustments for equity securities without a readily determinable market value, forward contracts and purchased options, presentation requirements for certain fair value option liabilities, fair value option liabilities denominated in a foreign currency, and transition guidance for equity securities without a readily determinable fair value. ASU 2018-03 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years beginning after June 15, 2018. Early adoption is permitted for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, as long as the Company has adopted ASU 2016-01. The Company is evaluating the requirements of this guidance. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In February 2018, the FASB Issued Accounting Standards Update No. 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income ("ASU 2018-02") . ASU 2018-02 provides entities with an option to reclassify stranded tax effects within Accumulated Other Comprehensive Income ("AOCI") to retained earnings in each period in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Act (or portion thereof) is recorded. ASU 2018-02 requires entities to disclose a description of the accounting policy for releasing income tax effects from AOCI; whether they elect to reclassify the stranded income tax effects from the Tax Act; and information about the other income tax effects that are reclassified. ASU 2018-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, and entities should apply the proposed amendments either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Act is recognized. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In August 2017, the FASB issued Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815), Targeted Improvements to Accounting for Hedging Activities ("ASU 2017-12") , which amends the hedge accounting recognition and presentation requirements in Topic 815. ASU 2017-12 makes targeted changes to the existing hedge accounting model to better align an entity’s financial reporting for hedging relationships with the entity’s risk management activities, and to reduce the complexity of, and simplify the application of, the hedge accounting model. Specifically, ASU 2017-12 expands the types of transactions eligible for hedge accounting, eliminates the requirement to separately measure and present hedge ineffectiveness, simplifies the way assessments of hedge ineffectiveness may be performed, relaxes the documentation requirements for entering into hedging positions, provides targeted improvements to fair value hedges of interest rate risk, and permits an entity to exclude the change in the fair value of cross-currency basis spreads in currency swaps from the assessment of hedge effectiveness. The standard also requires entities to provide new disclosures about the impact fair value and cash flow hedges have on their income statements and about cumulative basis adjustments arising from fair value hedges. The provisions of this guidance are to be applied using a modified retrospective approach to existing hedging relationships as of the adoption date. However, the transition provisions allow for certain elections at the date of adoption and entities may choose to apply any of the provided elections. ASU 2017-12 is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted, including adoption in any interim period. The Company early adopted the provisions of this guidance effective January 1, 2018. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In May 2017, the FASB issued Accounting Standards Update No. 2017-09, Compensation - Stock Compensation (Topic 718), Scope of Modification Accounting ("ASU 2017-09") , which amends the scope of modification accounting for share-based payment arrangements. ASU 2017-09 provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under Topic 718. Specifically, an entity would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. If an entity modifies its awards and concludes that it is not required to apply modification accounting under the standard, it must still consider whether the modification affects its application of other guidance. Additionally, if a significant modification does not result in incremental compensation cost, entities are required to disclose the “lack of” incremental compensation cost resulting from such significant modification. The standard also removes the guidance in Topic 718 stating that modification accounting is not required when an entity adds an antidilution provision as long as that modification is not made in contemplation of an equity restructuring. The provisions of this guidance are to be applied on a prospective basis to awards modified on or after the effective date. ASU 2017-09 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted, including adoption in any interim period. The Company adopted ASU 2017-09 effective January 1, 2018. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In March 2017, the FASB issued Accounting Standards Update No. 2017-07, Compensation - Retirement Benefits (Topic 715), Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost ("ASU 2017-07") , which amends the requirements in Topic 715 related to the income statement presentation of the components of net periodic benefit cost for an entity’s sponsored defined benefit pension and other postretirement plans. ASU 2017-07 requires entities to (1) disaggregate the current-service-cost component from the other components of net benefit cost (the “other components”) and present it with other current employee compensation costs in their income statements and (2) present the other components elsewhere in their income statements and outside of income from operations, and disclose the income statement lines that contain the other components if they are not presented on appropriately described separate lines. Additionally, the standard requires that only the service-cost component of net benefit cost is eligible for capitalization (e.g., as part of inventory or property, plant, and equipment). The change in income statement presentation requires retrospective application, while the change in capitalized benefit cost is to be applied prospectively. ASU 2017-07 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The standard provides a practical expedient that permits entities to use the components of cost disclosed in prior years as a basis for the retrospective application of the new income statement presentation. Entities need to disclose the use of the practical expedient. The Company adopted ASU 2017-07 effective January 1, 2018 using a retrospective approach for each period presented. For the three and six months ended July 2, 2017 , $1.8 million and $3.6 million , respectively, of net periodic pension credit previously presented within operating income has been presented outside of operating income in the line item "Interest and other expense, net" in the condensed consolidated statement of operations due to the retrospective adoption of ASU 2017-07. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows, other than the impact discussed above. In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (Topic 805), Clarifying the Definition of a Business ("ASU 2017-01"), which amends Topic 805 to provide a screen to determine when a set of assets and liabilities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. If the screen is not met, the standard (1) requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) removes the evaluation of whether a market participant could replace missing elements. The standard provides a framework to assist entities in evaluating whether both an input and a substantive process are present. The standard also provides a framework that includes two sets of criteria to consider that depend on whether a set has outputs and a more stringent criteria for sets without outputs. Lastly, the standard narrows the definition of the term "output" so that the term is consistent with how outputs are described in Topic 606, Revenue from Contracts with Customers . The provisions of this guidance are to be applied prospectively. ASU 2017-01 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted in limited circumstances. The Company adopted ASU 2017-01 effective January 1, 2018. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Statement of Cash Flows (Topic 230), Restricted Cash ("ASU 2016-18"), which amends Topic 230 to add or clarify guidance on the classification and presentation of restricted cash in the statement of cash flows. The standard requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The provisions of this guidance are to be applied using a retrospective transition method to each period presented. ASU 2016-18 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The Company adopted ASU 2016-18 effective January 1, 2018. For the six months ended July 2, 2017 , $17.2 million of changes in restricted cash balances that was previously presented within investing activities in the condensed consolidated statement of cash flows has been excluded from the cash flows used in investing activities and the effect of exchange rate changes increased by $0.2 million due to the retrospective adoption of ASU 2016-18. Restricted cash amounting to $17.3 million and $0.3 million at January 1, 2017 and July 2, 2017 , respectively, have been included with the cash and cash equivalents when reconciling the beginning of period and end of period total amounts on the condensed consolidated statement of cash flows for the six months ended July 2, 2017 . The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows, other than the impact discussed above. In October 2016, the FASB issued Accounting Standards Update No. 2016-16, Income Taxes (Topic 740), Intra-entity Transfer of Assets Other than Inventory ("ASU 2016-16"). ASU 2016-16 removes the prohibition in Topic 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. The standard requires entities to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The provisions of this guidance are to be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. ASU 2016-16 is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The Company adopted ASU 2016-16 on January 1, 2018. The adoption of the standard resulted in a decrease in the retained earnings at January 1, 2018 of approximately $2.0 million with corresponding increase in deferred tax assets of $10.7 million and decrease in prepaid taxes of $12.8 million related to prior years’ intra-entity transfers of assets other than inventory. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows, other than the impact discussed above. In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"). ASU 2016-13 changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The standard requires entities to use the expected loss impairment model and will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases and off-balance sheet credit exposures. Entities are required to estimate the lifetime “expected credit loss” for each applicable financial asset and record an allowance that, when deducted from the amortized cost basis of the financial asset, presents the net amount expected to be collected on the financial asset. The standard also amends the impairment model for available-for-sale (“AFS”) debt securities and requires entities to determine whether all or a portion of the unrealized loss on an AFS debt security is a credit loss. An entity will recognize an allowance for credit losses on an AFS debt security as a contra-account to the amortized cost basis rather than as a direct reduction of the amortized cost basis of the investment. The provisions of this guidance are to be applied using a modified-retrospective approach. A prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. ASU 2016-13 is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years. Early adoption is permitted for annual periods beginning after December 15, 2018, and interim periods therein. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases ("ASU 2016-02"). ASU 2016-02 requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease of assets will primarily depend on its classification as a finance or operating lease. ASU 2016-02 also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The provisions of this guidance are effective for annual periods beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. ASU 2016-02 is to be applied using a modified retrospective approach. The Company is evaluating the requirements of this guidance and has not yet determined the impact of the adoption on its consolidated financial position, results of operations and cash flows. The Company does not intend to early adopt the provisions of this standard. In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). Under this new guidance, an entity should use a five-step process to recognize revenue, depicting the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires new disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. Subsequent to the issuance of the standard, the FASB decided to defer the effective date for one year to annual reporting periods beginning after December 15, 2017, with early adoption permitted for annual reporting periods beginning after December 15, 2016. In November 2017, the FASB also issued Accounting Standards Update No. 2017-14, Income Statement-Reporting Comprehensive Income (Topic 220), Revenue Recognition (Topic 605), and Revenue from Contracts with Customers (Topic 606) . ASU 2017-14 includes amendments to certain SEC paragraphs within the FASB Accounting Standards Codification ("Codification"). ASU 2017-14 amends the Codification to incorporate SEC Staff Accounting Bulletin No. 116 and SEC Interpretive Release on Vaccines for Federal Government Stockpiles (SEC Release No. 33-10403) to align existing SEC staff guidance with Revenue from Contracts with Customers (Topic 606). In May 2016, the FASB also issued Accounting Standards Update No. 2016-12, Revenue from Contracts with Customers (Topic 606), Narrow-Scope Improvements and Practical Expedients ("ASU 2016-12") , which amended its revenue recognition guidance in ASU 2014-09 on transition, collectability, non-cash consideration, contract modifications and completed contracts at transition and the presentation of sales and other similar taxes collected from customers. In April 2016, the FASB also issued Accounting Standards Update No. 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing ("ASU 2016-10") , which amended its revenue recognition guidance in ASU 2014-09 on identifying performance obligations to allow entities to disregard items that are immaterial in the context of the contract, clarify when a promised good or service is separately identifiable (i.e., distinct within the context of the contract) and allow an entity to elect to account for the cost of shipping and handling performed after control of a good has been transferred to the customer as a fulfillment cost (i.e., an expense). ASU 2016-10 also clarifies how an entity should evaluate the nature of its promise in granting a license of intellectual property ("IP") and requires entities to classify IP in one of two categories: functional IP or symbolic IP, which will determine whether it recognizes revenue over time or at a point in time. ASU 2016-10 also addresses how entities should consider license renewals and restrictions and apply the exception for sales- and usage-based royalties received in exchange for licenses of IP. In March 2016, the FASB also issued Accounting Standards Update No. 2016-08, Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net) ("ASU 2016-08"), which amended the principal-versus-agent implementation guidance and illustrations in ASU 2014-09. ASU 2016-08 clarifies that an entity should evaluate when it is the principal or agent for each specified good or service promised in a contract with a customer. ASU 2017-14, ASU 2016-12, ASU 2016-10, ASU 2016-08 and ASU 2014-09 may be adopted either using a full retrospective approach or a modified retrospective approach. The Company adopted these standards beginning on January 1, 2018 using the modified retrospective approach only to contracts not completed as of January 1, 2018 . The most significant impact of the standards relates to the accounting for certain transactions with multiple elements or “bundled” arrangements. Specifically, for sales of software subscriptions or sales of licenses and maintenance, the Company will recognize the license revenue predominantly at the time of billing and delivery rather than recognizing the entire sales price ratably over the maintenance period, which is the Company's current practice. In addition, for certain sales of instruments that include customer-specified acceptance criteria, the Company will recognize revenue when the customer obtains control of the instrument which is typically upon delivery or when title has transferred to the customer, as the Company believes acceptance is perfunctory. The Company will also capitalize incremental commission fees as a result of obtaining contracts when these fees are recoverable and will amortize the assets based on the transfer of goods or services to which the assets relate which typically range from two to six years. The adoption of the standards resulted in an increase in retained earnings at January 1, 2018 of approximately $10.2 million for the cumulative effect of initially applying the standards as of that date. In addition, the adoption of the standards resulted primarily in a reduction in deferred revenue of approximately $11.5 million , mainly driven by the upfront recognition of license revenue and certain multi-year software subscriptions, and an increase in deferred income tax liability of approximately $3.0 million for the tax impact of the cumulative adjustments. The cumulative effect of recognizing instrument sales upon delivery or transfer of title and capitalizing the incremental commission fees were not material at January 1, 2018. The adoption of the standards had no impact to cash from or used in operating, investing, or financing activities in the Company's consolidated statement of cash flows at January 1, 2018. Refer to Note 3, Changes in Accounting Policies, for the impact of adoption of the standards on the Company's condensed consolidated financial statements for the quarter ended July 1, 2018 . Also refer to Note 2, Revenue, for the disclosures required by the standards.
Revenue Recognition, Policy [Policy Text Block]	The Company adopted ASC 606, Revenue from Contracts with Customers ("ASC 606"), with a date of the initial application of January 1, 2018. As a result, the Company has changed its accounting policy for revenue recognition as detailed below. The Company applied ASC 606 using the modified retrospective method only to contracts that are not completed contracts as of January 1, 2018, and the cumulative effect of initially applying ASC 606 is recognized as an adjustment to the beginning retained earnings. Therefore, the comparative information has not been adjusted and continues to be reported under ASC 605. The details of the significant changes and quantitative impact of the changes are disclosed below. A. Sales of software subscriptions or sales of licenses and maintenance in bundled arrangements The Company previously recognized revenue from software licenses sold together with maintenance and/or consulting services upon shipment using the residual method, provided that the undelivered items in the arrangement have value to the customer on a stand-alone basis and vendor-specific objective evidence ("VSOE") of fair value can be determined. If VSOE of fair value for the undelivered elements cannot be established, the Company deferred all revenue from the arrangement until the earlier of the point at which such sufficient VSOE does exist or all elements of the arrangement have been delivered, or if the undelivered element is maintenance, then the Company recognized the entire fee ratably over the maintenance period. Under ASC 606, the total consideration in the contract is allocated to all products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the list prices at which the Company sells the software license, software subscription, maintenance and/or consulting services. Accordingly, the Company now recognizes higher license revenue upfront and less service revenue over time. B. Sales of instruments The Company previously recognized revenue from sale of instruments when persuasive evidence of an arrangement existed, delivery had occurred, the price to the buyer was fixed or determinable, and collectability was reasonably assured. For certain sales of instruments that included customer-specified acceptance criteria, the Company previously recognized revenue after the acceptance criteria had been met. Under ASC 606, revenue is recognized when the Company satisfies a performance obligation by transferring control of the product to a customer. Accordingly, the Company now recognizes product revenue upon delivery or when title has transferred to the customer, as the Company believes acceptance is perfunctory. C. Sales commissions The Company previously recognized commission fees related to sales of products and services as selling expenses when they were incurred. Under ASC 606, the Company capitalizes those commission fees as costs of obtaining a contract, when they are incremental and, if they are expected to be recovered, the Company amortizes them consistently with the pattern of transfer of the product or service to which the asset relates. If the expected amortization period is one year or less, the commission fee is expensed when incurred.

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jul. 01, 2018
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue [Table Text Block]	In the following tables, revenue is disaggregated by primary geographical market, end-markets and timing of revenue recognition. The tables also include a reconciliation of the disaggregated revenue with the reportable segments revenue. Reportable Segments Three Months Ended July 1, 2018 Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 170,973 $ 98,395 $ 269,368 Europe 127,646 69,700 197,346 Asia 132,009 104,639 236,648 $ 430,628 $ 272,734 $ 703,362 Primary end-markets Diagnostics $ — $ 272,734 $ 272,734 Life sciences 233,906 — 233,906 Applied markets 196,722 — 196,722 $ 430,628 $ 272,734 $ 703,362 Timing of revenue recognition Products and services transferred at a point in time $ 312,815 $ 252,401 $ 565,216 Services transferred over time 117,813 20,333 138,146 $ 430,628 $ 272,734 $ 703,362 Reportable Segments Six Months Ended July 1, 2018 Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 328,467 $ 186,929 $ 515,396 Europe 247,019 137,412 384,431 Asia 251,667 195,840 447,507 $ 827,153 $ 520,181 $ 1,347,334 Primary end-markets Diagnostics $ — $ 520,181 $ 520,181 Life sciences 453,616 — 453,616 Applied markets 373,537 — 373,537 $ 827,153 $ 520,181 $ 1,347,334 Timing of revenue recognition Products and services transferred at a point in time $ 583,588 $ 478,869 $ 1,062,457 Services transferred over time 243,565 41,312 284,877 $ 827,153 $ 520,181 $ 1,347,334

Changes in Accounting Policie29

Changes in Accounting Policies (Tables)	6 Months Ended
	Jul. 01, 2018
Accounting Policies [Abstract]
Schedule of Prospective Adoption of New Accounting Pronouncements [Table Text Block]	Impacts on financial statements The following tables summarize the impacts of ASC 606 adoption on the Company's condensed consolidated financial statements for the quarter ended July 1, 2018 . Consolidated Balance Sheet As reported Adjustments Balances without adoption of ASC 606 (In thousands) Cash and cash equivalents $ 163,392 $ — $ 163,392 Accounts receivable, net 564,041 (12,505 ) 551,536 Inventories 366,961 7,556 374,517 Other current assets 108,019 (679 ) 107,340 Property, plant and equipment, net 304,538 — 304,538 Intangible assets, net 1,270,867 — 1,270,867 Goodwill 2,940,825 — 2,940,825 Other assets, net 239,135 — 239,135 Total assets $ 5,957,778 $ (5,628 ) $ 5,952,150 Current portion of long-term debt $ 17,315 $ — $ 17,315 Accounts payable 197,128 — 197,128 Accrued restructuring and contract termination charges 7,443 — 7,443 Accrued expenses and other current liabilities 488,642 15,577 504,219 Current liabilities of discontinued operations 2,165 — 2,165 Long-term debt 1,983,953 — 1,983,953 Long-term liabilities 743,955 — 743,955 Total liabilities 3,440,601 15,577 3,456,178 Commitments and contingencies Preferred stock — — — Common stock 110,716 — 110,716 Capital in excess of par value 73,740 — 73,740 Retained earnings 2,463,287 (21,205 ) 2,442,082 Accumulated other comprehensive loss (130,566 ) — (130,566 ) Total stockholders’ equity 2,517,177 (21,205 ) 2,495,972 Total liabilities and stockholders’ equity $ 5,957,778 $ (5,628 ) $ 5,952,150 Consolidated Statement of Operations Three Months Ended July 1, 2018 As reported Adjustments Balances without adoption of ASC 606 (In thousands) Product revenue $ 495,608 $ (9,178 ) $ 486,430 Service revenue 207,754 — 207,754 Total revenue 703,362 (9,178 ) 694,184 Cost of product revenue 229,723 (3,566 ) 226,157 Cost of service revenue 133,499 — 133,499 Total cost of revenue 363,222 (3,566 ) 359,656 Selling, general and administrative expenses 204,880 74 204,954 Research and development expenses 47,196 — 47,196 Operating income from continuing operations 88,064 (5,686 ) 82,378 Interest and other expense, net 16,356 — 16,356 Income from continuing operations before income taxes 71,708 (5,686 ) 66,022 Provision for income taxes 7,035 (1,499 ) 5,536 Income from continuing operations 64,673 (4,187 ) 60,486 Loss on disposition of discontinued operations before income taxes (551 ) — (551 ) Provision for income taxes on discontinued operations and dispositions 59 — 59 Loss from discontinued operations and dispositions (610 ) — (610 ) Net income $ 64,063 $ (4,187 ) $ 59,876 Consolidated Statement of Operations Six Months Ended July 1, 2018 As reported Adjustments Balances without adoption of ASC 606 (In thousands) Product revenue $ 943,216 $ (22,364 ) $ 920,852 Service revenue 404,118 — 404,118 Total revenue 1,347,334 (22,364 ) 1,324,970 Cost of product revenue 449,979 (7,682 ) 442,297 Cost of service revenue 264,993 — 264,993 Total cost of revenue 714,972 (7,682 ) 707,290 Selling, general and administrative expenses 404,605 253 404,858 Research and development expenses 93,180 — 93,180 Restructuring and contract termination charges, net 6,578 — 6,578 Operating income from continuing operations 127,999 (14,935 ) 113,064 Interest and other expense, net 27,786 — 27,786 Income from continuing operations before income taxes 100,213 (14,935 ) 85,278 Provision for income taxes 9,505 (3,939 ) 5,566 Income from continuing operations 90,708 (10,996 ) 79,712 Loss on disposition of discontinued operations before income taxes (551 ) — (551 ) Provision for income taxes on discontinued operations and dispositions 70 — 70 Loss from discontinued operations and dispositions (621 ) — (621 ) Net income $ 90,087 $ (10,996 ) $ 79,091 The adoption of ASC 606 increased comprehensive income by $4.2 million and $11.0 million in the Company's condensed consolidated statement of comprehensive income for the three and six months ended July 1, 2018 , respectively. The adoption of ASC 606 had no impact on cash from or used in operating, investing, or financing activities in the Company's condensed consolidated statement of cash flows as of and for the six months ended July 1, 2018

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Information [Table Text Block]		The following unaudited pro forma information presents the combined financial results for the Company and EUROIMMUN as if the acquisition of EUROIMMUN had been completed at the beginning of fiscal year 2016: Three Months Ended July 2, 2017 Six Months Ended July 2, 2017 (In thousands, except per share data) Pro Forma Statement of Operations Information (Unaudited): Revenue $ 625,525 $ 1,206,079 Income from continuing operations 53,024 78,617 Basic earnings per share: Income from continuing operations $ 0.48 $ 0.72 Diluted earnings per share: Income from continuing operations $ 0.48 $ 0.71 The unaudited pro forma information for the three and six months ended July 2, 2017 has been calculated after applying the Company's accounting policies and the impact of acquisition date fair value adjustments. These pro forma condensed consolidated financial results have been prepared for comparative purposes only and include certain adjustments, such as increased interest expense on debt obtained to finance the transaction and increased amortization for the acquired intangible assets recorded at fair value. The pro forma information does not reflect the effect of costs or synergies that would have been expected to result from the integration of the acquisition. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combination occurred at the beginning of each period presented, or of future results of the consolidated entities.
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The total purchase price for the acquisitions in fiscal year 2018 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: 2018 Acquisitions (In thousands) Fair value of business combination: Cash payments $ 34,942 Other liability 2,354 Contingent consideration 1,700 Working capital and other adjustments (101 ) Less: cash acquired (370 ) Total $ 38,525 Identifiable assets acquired and liabilities assumed: Current assets $ 2,750 Property, plant and equipment 311 Identifiable intangible assets: Core technology 15,957 Trade names 610 Customer relationships 5,100 Goodwill 19,793 Deferred taxes (2,523 ) Liabilities assumed (3,473 ) Total $ 38,525 The total purchase price for the acquisitions in fiscal year 2017 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: EUROIMMUN Other Acquisitions (In thousands) Fair value of business combination: Cash payments $ 1,413,780 $ 140,861 Other liability — 1,273 Working capital and other adjustments — (93 ) Less: cash acquired (25,018 ) (2,439 ) Total $ 1,388,762 $ 139,602 Identifiable assets acquired and liabilities assumed: Current assets $ 121,174 $ 16,268 Property, plant and equipment 129,964 11,356 Other assets 49,944 1,691 Identifiable intangible assets: Core technology 160,000 12,400 Trade names 36,000 3,000 Customer relationships 710,000 43,700 In-process research and development ("IPR&D") 1,400 — Goodwill 582,692 75,250 Deferred taxes (253,354 ) (15,735 ) Liabilities assumed (87,701 ) (8,328 ) Debt assumed (61,357 ) — Total $ 1,388,762 $ 139,602

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Jul. 01, 2018
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	The summary pre-tax operating results of the discontinued operations, were as follows for the three and six months ended: Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Revenue $ — $ 8,249 $ — $ 44,343 Cost of revenue — 8,138 — 32,933 Selling, general and administrative expenses — 1,926 — 5,869 Research and development expenses — 1,294 — 4,891 (Loss) income from discontinued operations before income taxes $ — $ (3,109 ) $ — $ 650

Restructuring and Lease Charg32

Restructuring and Lease Charges, Net (Tables)	6 Months Ended
	Jul. 01, 2018
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Plan Activity [Table Text Block]	The following table summarizes the reductions in headcount, the initial restructuring or contract termination charges by reporting segment, and the dates by which payments were substantially completed, or the dates by which payments are expected to be substantially completed, for restructuring actions implemented during fiscal years 2018 and 2017 in continuing operations: Workforce Reductions Closure of Excess Facility Total (Expected) Date Payments Substantially Completed by Headcount Reduction Discovery & Analytical Solutions Diagnostics Discovery & Analytical Solutions Diagnostics Severance Excess Facility (In thousands, except headcount data) Q1 2018 Plan 47 $ 5,096 $ 902 $ — $ — $ 5,998 Q2 FY2019 — Q4 2017 Plan 29 1,680 255 — — 1,935 Q1 FY2019 — Q3 2017 Plan 27 1,321 1,021 — — 2,342 Q4 FY2018 — Q1 2017 Plan 90 5,000 1,631 33 33 6,697 Q4 FY2018 Q4 FY2018
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the Company's restructuring and contract termination accrual balances and related activity by restructuring plan, as well as contract termination accrual balances and related activity, during the six months ended July 1, 2018 : Balance at December 31, 2017 2018 Charges 2018 Changes in Estimates, Net 2018 Amounts Paid Balance at July 1, 2018 (In thousands) Severance: Q1 2018 Plan $ — $ 5,998 $ — $ (3,606 ) $ 2,392 Q4 2017 Plan 1,919 — — (1,316 ) 603 Q3 2017 Plan 2,072 — — (863 ) 1,209 Q1 2017 Plan 2,498 — — (1,073 ) 1,425 Facility: Q1 2017 Plan 33 — — (22 ) 11 Previous Plans 4,399 — 353 (1,435 ) 3,317 Restructuring 10,921 5,998 353 (8,315 ) 8,957 Contract Termination 3,048 — 227 — 3,275 Total Restructuring and Contract Termination $ 13,969 $ 5,998 $ 580 $ (8,315 ) $ 12,232

Interest and Other Expense (I33

Interest and Other Expense (Income), Net (Tables)	6 Months Ended
	Jul. 01, 2018
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and other expense, net, consisted of the following: Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Interest income $ (173 ) $ (490 ) $ (438 ) $ (710 ) Interest expense 16,411 10,672 34,061 21,536 Loss on disposition of businesses and assets, net — 301 — 301 Other expense (income), net 118 (7,092 ) (5,837 ) (7,908 ) Total interest and other expense, net $ 16,356 $ 3,391 $ 27,786 $ 13,219

Inventories, Net (Tables)

Inventories, Net (Tables)	6 Months Ended
	Jul. 01, 2018
Inventory Disclosure [Abstract]
Schedule of Net Inventories	Inventories as of July 1, 2018 and December 31, 2017 consisted of the following: July 1, December 31, (In thousands) Raw materials $ 128,927 $ 122,100 Work in progress 21,376 18,452 Finished goods 216,658 211,123 Total inventories $ 366,961 $ 351,675

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jul. 01, 2018
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	The total provision for income taxes included in the condensed consolidated statement of operations consisted of the following: Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Continuing operations $ 7,035 $ 8,066 $ 9,505 $ 11,987 Discontinued operations 59 35,925 70 37,143 Total $ 7,094 $ 43,991 $ 9,575 $ 49,130

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jul. 01, 2018
Earnings Per Share [Abstract]
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations	The following table reconciles the number of shares utilized in the earnings per share calculations: Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Number of common shares—basic 110,477 109,894 110,386 109,681 Effect of dilutive securities: Stock options 786 668 824 636 Restricted stock awards 189 200 181 167 Number of common shares—diluted 111,452 110,762 111,391 110,484 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 346 457 339 558

Industry Segment Information (T

Industry Segment Information (Tables)	6 Months Ended
	Jul. 01, 2018
Segment Reporting [Abstract]
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations	Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below: Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Discovery & Analytical Solutions Product revenue $ 263,325 $ 227,290 $ 501,020 $ 442,450 Service revenue 167,303 155,838 326,133 302,438 Total revenue 430,628 383,128 827,153 744,888 Operating income from continuing operations 64,665 51,124 100,862 81,346 Diagnostics Product revenue 232,283 127,711 442,196 246,265 Service revenue 40,451 36,123 77,985 69,924 Total revenue 272,734 163,834 520,181 316,189 Operating income from continuing operations 38,780 36,947 57,174 69,663 Corporate Operating loss from continuing operations (15,381 ) (13,888 ) (30,037 ) (27,015 ) Continuing Operations Product revenue 495,608 355,001 943,216 688,715 Service revenue 207,754 191,961 404,118 372,362 Total revenue 703,362 546,962 1,347,334 1,061,077 Operating income from continuing operations 88,064 74,183 127,999 123,994 Interest and other expense, net (see Note 7) 16,356 3,391 27,786 13,219 Income from continuing operations before income taxes $ 71,708 $ 70,792 $ 100,213 $ 110,775

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jul. 01, 2018
Stockholders' Equity Note [Abstract]
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive loss consisted of the following: July 1, December 31, (In thousands) Foreign currency translation adjustments $ (130,675 ) $ (46,582 ) Unrecognized prior service costs, net of income taxes 322 322 Unrealized net losses on securities, net of income taxes (213 ) (258 ) Accumulated other comprehensive loss $ (130,566 ) $ (46,518 )

Stock Plans (Tables)

Stock Plans (Tables)	6 Months Ended
	Jul. 01, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Total Compensation Recognized Related to Outstanding Equity Awards	The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock option grants, restricted stock awards, performance restricted stock units, performance units and stock awards, included in the Company’s condensed consolidated statements of operations for the three and six months ended July 1, 2018 and July 2, 2017 : Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Cost of revenue $ 358 $ 281 $ 663 $ 541 Research and development expenses 386 377 694 704 Selling, general and administrative expenses 6,072 6,183 10,791 10,522 Total stock-based compensation expense $ 6,816 $ 6,841 $ 12,148 $ 11,767 The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $1.6 million and $4.5 million for the three and six months ended July 1, 2018 , respectively. The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $5.1 million and $8.0 million for the three and six months ended July 2, 2017 , respectively. Stock-based compensation costs capitalized as part of inventory were $0.4 million as of each of July 1, 2018 and July 2, 2017
Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model	The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows: Three and Six Months Ended July 1, July 2, Risk-free interest rate 2.9 % 1.8 % Expected dividend yield 0.4 % 0.5 % Expected term 5 years 5 years Expected stock volatility 20.7 % 22.4 %
Summary of Stock Option Activity	The following table summarizes stock option activity for the six months ended July 1, 2018 : Number of Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term Total Intrinsic Value (In thousands) (In years) (In millions) Outstanding at December 31, 2017 2,154 $ 42.77 Granted 342 77.61 Exercised (194 ) 42.98 Forfeited (10 ) 59.61 Outstanding at July 1, 2018 2,292 $ 47.88 3.9 $ 58.1 Exercisable at July 1, 2018 1,464 $ 40.05 2.9 $ 48.6
Summary of Restricted Stock Award Activity	The following table summarizes restricted stock award activity for the six months ended July 1, 2018 : Number of Shares Weighted- Average Grant- Date Fair Value (In thousands) Nonvested at December 31, 2017 496 $ 50.30 Granted 194 75.37 Vested (181 ) 49.54 Forfeited (12 ) 55.62 Nonvested at July 1, 2018 497 $ 60.26

Goodwill and Intangible Asset40

Goodwill and Intangible Assets, Net (Tables)	6 Months Ended
	Jul. 01, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the six months ended July 1, 2018 were as follows: Discovery & Analytical Solutions Diagnostics Consolidated (In thousands) Balance at December 31, 2017 $ 1,344,235 $ 1,657,963 $ 3,002,198 Foreign currency translation (22,053 ) (26,648 ) (48,701 ) Acquisitions and other 10,191 (22,863 ) (12,672 ) Balance at July 1, 2018 $ 1,332,373 $ 1,608,452 $ 2,940,825
Identifiable Intangible Asset Balances	Identifiable intangible asset balances at July 1, 2018 and December 31, 2017 by category were as follows: July 1, December 31, (In thousands) Patents $ 39,953 $ 39,959 Less: Accumulated amortization (36,389 ) (35,085 ) Net patents 3,564 4,874 Trade names and trademarks 79,586 80,974 Less: Accumulated amortization (31,400 ) (28,250 ) Net trade names and trademarks 48,186 52,724 Licenses 51,720 53,300 Less: Accumulated amortization (44,062 ) (42,635 ) Net licenses 7,658 10,665 Core technology 478,499 471,740 Less: Accumulated amortization (263,080 ) (244,916 ) Net core technology 215,419 226,824 Customer relationships 1,126,608 1,141,511 Less: Accumulated amortization (276,368 ) (242,840 ) Net customer relationships 850,240 898,671 IPR&D 81,152 88,025 Less: Accumulated amortization (5,936 ) (5,427 ) Net IPR&D 75,216 82,598 Net amortizable intangible assets 1,200,283 1,276,356 Non-amortizing intangible asset: Trade name 70,584 70,584 Total $ 1,270,867 $ 1,346,940

Warranty Reserves (Tables)

Warranty Reserves (Tables)	6 Months Ended
	Jul. 01, 2018
Product Warranties Disclosures [Abstract]
Warranty Reserve Activity	A summary of warranty reserve activity for the three and six months ended July 1, 2018 and July 2, 2017 is as follows: Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Balance at beginning of period $ 8,786 $ 8,937 $ 9,050 $ 9,012 Provision charged to income 3,515 3,391 6,685 6,380 Payments (3,490 ) (3,412 ) (6,967 ) (7,137 ) Adjustments to previously provided warranties, net 446 (24 ) 336 515 Foreign currency translation and acquisitions (314 ) 196 (161 ) 318 Balance at end of period $ 8,943 $ 9,088 $ 8,943 $ 9,088

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	6 Months Ended
	Jul. 01, 2018
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost (Credit)	The following table summarizes the components of net periodic pension credit for the Company’s various defined benefit employee pension and postretirement plans for the three and six months ended July 1, 2018 and July 2, 2017 : Defined Benefit Pension Benefits Postretirement Medical Benefits Three Months Ended July 1, July 2, July 1, July 2, (In thousands) Service and administrative costs $ 1,712 $ 1,222 $ 26 $ 23 Interest cost 4,057 4,133 30 31 Expected return on plan assets (7,310 ) (6,541 ) (313 ) (278 ) Amortization of prior service costs (41 ) (48 ) — — Net periodic pension credit $ (1,582 ) $ (1,234 ) $ (257 ) $ (224 ) Defined Benefit Pension Benefits Postretirement Medical Benefits Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Service and administrative costs $ 3,468 $ 2,436 $ 53 $ 46 Interest cost 8,161 8,260 60 62 Expected return on plan assets (14,656 ) (13,041 ) (627 ) (557 ) Amortization of prior service costs (82 ) (95 ) — — Net periodic benefit credit $ (3,109 ) $ (2,440 ) $ (514 ) $ (449 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jul. 01, 2018
Fair Value Disclosures [Abstract]
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis	The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of July 1, 2018 and December 31, 2017 classified in one of the three classifications described above: Fair Value Measurements at July 1, 2018 Using: Total Carrying Value at July 1, 2018 Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable (Level 3) (In thousands) Marketable securities $ 2,271 $ 2,271 $ — $ — Foreign exchange derivative assets 3,367 — 3,367 — Foreign exchange derivative liabilities (535 ) — (535 ) — Contingent consideration (74,093 ) — — (74,093 ) Fair Value Measurements at December 31, 2017 Using: Total Carrying Value at December 31, 2017 Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 2,208 $ 2,208 $ — $ — Foreign exchange derivative assets 1,431 — 1,431 — Foreign exchange derivative liabilities (23,638 ) — (23,638 ) — Contingent consideration (65,328 ) — — (65,328 )
Reconciliation of Beginning and Ending Level 3 Net Liabilities	A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, (In thousands) Balance at beginning of period $ (65,445 ) $ (63,978 ) $ (65,328 ) $ (63,201 ) Additions (1,700 ) — (1,700 ) — Amounts paid and foreign currency translation — — — 34 Change in fair value (included within selling, general and administrative expenses) (6,948 ) (98 ) (7,065 ) (909 ) Balance at end of period $ (74,093 ) $ (64,076 ) $ (74,093 ) $ (64,076 )

Basis of Presentation (Basis of

Basis of Presentation (Basis of Presentation) (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2018	Jan. 01, 2017
Basis of Presentation [Line Items]
Defined Benefit Plan, Other Cost (Credit)	$ (2,500,000)	$ (1,800,000)	$ (5,000,000)	$ (3,600,000)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents			(4,351,000)	14,928,000
Restricted Cash	$ 204,000	250,000	204,000	250,000
Operating Cycle						52
Accounting Standards Update 2014-09 [Member]
Basis of Presentation [Line Items]
Cumulative Effect of New Accounting Principle in Period of Adoption							$ 10,200,000
Impact of New Accounting Principle, Deferred Revenue							(11,500,000)
Tax impact of Cumulative Adjustments, Deferred Income Tax							3,000,000
Accounting Standards Update 2016-16 [Member]
Basis of Presentation [Line Items]
Cumulative Effect of New Accounting Principle in Period of Adoption							2,000,000
Impact of New Accounting Principles, Deferred Tax Assets							10,700,000
Impact of New Accounting Principles, Prepaid Taxes							$ (12,800,000)
Accounting Standards Update 2016-18 [Member]
Basis of Presentation [Line Items]
Increase (Decrease) in Restricted Cash				(17,203,000)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents				(200,000)
Restricted Cash		251,000		$ 251,000				$ 17,302,000
Accounting Standards Update 2017-07 [Member]
Basis of Presentation [Line Items]
Defined Benefit Plan, Other Cost (Credit)		$ 1,800,000	$ 3,600,000
Scenario, Forecast [Member]
Basis of Presentation [Line Items]
Operating Cycle					52

Revenue (Details)

Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017	Jan. 01, 2018
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 703,362	$ 546,962	$ 1,347,334	$ 1,061,077
Contract with Customer, Asset and Liability [Abstract]
Contract with Customer, Asset, Net, Current	28,400		28,400		$ 22,700
Contract with Customer, Liability, Current	26,900		26,900		$ 29,000
Contract with Customer, Liability, Revenue Recognized			(38,200)
Increase (Decrease) in Unbilled Receivables			36,700
Unbilled Receivables Transferred To Accounts Receivables			(31,100)
Contract with Customer, Liability, Increase (Decrease)			36,100
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	565,216		1,062,457
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	138,146		284,877
Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	269,368		515,396
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	197,346		384,431
Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	236,648		447,507
Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	430,628	383,128	827,153	744,888
Discovery & Analytical Solutions [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	312,815		583,588
Discovery & Analytical Solutions [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	117,813		243,565
Discovery & Analytical Solutions [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	170,973		328,467
Discovery & Analytical Solutions [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	127,646		247,019
Discovery & Analytical Solutions [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	132,009		251,667
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	272,734	$ 163,834	520,181	$ 316,189
Diagnostics [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	252,401		478,869
Diagnostics [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	20,333		41,312
Diagnostics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	98,395		186,929
Diagnostics [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	69,700		137,412
Diagnostics [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	104,639		195,840
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	272,734		520,181
Diagnostics [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0		0
Diagnostics [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	272,734		520,181
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	233,906		453,616
Life Sciences [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	233,906		453,616
Life Sciences [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0		0
Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	196,722		373,537
Applied Markets [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	196,722		373,537
Applied Markets [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 0		$ 0

Changes in Accounting Policie46

Changes in Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ (703,362)	$ (546,962)	$ (1,347,334)	$ (1,061,077)
Cost of Revenue	363,222	289,360	714,972	563,719
Selling, general and administrative expenses	204,880	149,859	404,605	296,867
Research and development expenses	47,196	33,560	93,180	66,846
Restructuring and contract termination charges, net	0	0	6,578	9,651
Operating income (loss) from continuing operations	88,064	74,183	127,999	123,994
Nonoperating Income (Expense)	16,356	3,391	27,786	13,219
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	71,708	70,792	100,213	110,775
Provision for income taxes	7,035	8,066	9,505	11,987
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent	64,673	62,726	90,708	98,788
(Loss) income from discontinued operations before income taxes	0	(3,109)	0	650
(Loss) gain on disposition of discontinued operations before income taxes	(551)	180,377	(551)	180,377
Cash and cash equivalents	163,392	616,308	163,392	616,308	$ 202,134
Accounts receivable, net	(564,041)		(564,041)		(552,304)
Inventories	366,961		366,961		351,675
Other current assets	(108,019)		(108,019)		(93,842)
Property, Plant and Equipment, Net	304,538		304,538		298,066
Intangible assets, net	1,270,867		1,270,867		1,346,940
Goodwill	2,940,825		2,940,825		3,002,198
Other assets, net	239,135		239,135		244,304
Assets	(5,957,778)		(5,957,778)		(6,091,463)
Current portion of long-term debt	17,315		17,315		217,306
Accounts payable	197,128		197,128		222,093
Accrued expenses and other current liabilities	7,443		7,443		8,759
Accrued expenses and other current liabilities	488,642		488,642		500,642
Current liabilities of discontinued operations	2,165		2,165		2,102
Long-term debt	1,983,953		1,983,953		1,788,803
Long-term liabilities	743,955		743,955		848,570
Liabilities	3,440,601		3,440,601		3,588,275
Preferred Stock, Value, Issued	0		0		0
Common Stock, Value, Issued	110,716		110,716		110,361
Capital in excess of par value	73,740		73,740		58,828
Retained earnings	2,463,287		2,463,287		2,380,517
Accumulated other comprehensive loss	(130,566)		(130,566)		(46,518)
Stockholders' Equity Attributable to Parent	2,517,177		2,517,177		2,503,188
Liabilities and Equity	(5,957,778)		(5,957,778)		$ (6,091,463)
Discontinued Operation, Tax Effect of Discontinued Operation	59	35,925	70	37,143
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	(610)	141,343	(621)	143,884
Net income	64,063	204,069	90,087	242,672
Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	(9,178)		(22,364)
Cost of Revenue	3,566		7,682
Selling, general and administrative expenses	74		253
Research and development expenses	0		0
Restructuring and contract termination charges, net			0
Operating income (loss) from continuing operations	(5,686)		(14,935)
Nonoperating Income (Expense)	0		0
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	(5,686)		(14,935)
Provision for income taxes	(1,499)		(3,939)
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent	(4,187)		(10,996)
(Loss) gain on disposition of discontinued operations before income taxes	0		0
Cash and cash equivalents	0		0
Accounts receivable, net	(12,505)		(12,505)
Inventories	7,556		7,556
Other current assets	(679)		(679)
Property, Plant and Equipment, Net	0		0
Intangible assets, net	0		0
Goodwill	0		0
Other assets, net	0		0
Assets	(5,628)		(5,628)
Current portion of long-term debt	0		0
Accounts payable	0		0
Accrued expenses and other current liabilities	0		0
Accrued expenses and other current liabilities	15,577		15,577
Current liabilities of discontinued operations	0		0
Long-term debt	0		0
Long-term liabilities	0		0
Liabilities	15,577		15,577
Preferred Stock, Value, Issued	0		0
Common Stock, Value, Issued	0		0
Capital in excess of par value	0		0
Retained earnings	(21,205)		(21,205)
Accumulated other comprehensive loss	0		0
Stockholders' Equity Attributable to Parent	(21,205)		(21,205)
Liabilities and Equity	(5,628)		(5,628)
Discontinued Operation, Tax Effect of Discontinued Operation	0		0
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	0		0
Net income	(4,187)		(10,996)
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	(694,184)		(1,324,970)
Cost of Revenue	359,656		707,290
Selling, general and administrative expenses	204,954		404,858
Research and development expenses	47,196		93,180
Restructuring and contract termination charges, net			6,578
Operating income (loss) from continuing operations	82,378		113,064
Nonoperating Income (Expense)	16,356		27,786
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	66,022		85,278
Provision for income taxes	5,536		5,566
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent	60,486		79,712
(Loss) gain on disposition of discontinued operations before income taxes	(551)		(551)
Cash and cash equivalents	163,392		163,392
Accounts receivable, net	(551,536)		(551,536)
Inventories	374,517		374,517
Other current assets	(107,340)		(107,340)
Property, Plant and Equipment, Net	304,538		304,538
Intangible assets, net	1,270,867		1,270,867
Goodwill	2,940,825		2,940,825
Other assets, net	239,135		239,135
Assets	(5,952,150)		(5,952,150)
Current portion of long-term debt	17,315		17,315
Accounts payable	197,128		197,128
Accrued expenses and other current liabilities	7,443		7,443
Accrued expenses and other current liabilities	504,219		504,219
Current liabilities of discontinued operations	2,165		2,165
Long-term debt	1,983,953		1,983,953
Long-term liabilities	743,955		743,955
Liabilities	3,456,178		3,456,178
Preferred Stock, Value, Issued	0		0
Common Stock, Value, Issued	110,716		110,716
Capital in excess of par value	73,740		73,740
Retained earnings	2,442,082		2,442,082
Accumulated other comprehensive loss	(130,566)		(130,566)
Stockholders' Equity Attributable to Parent	2,495,972		2,495,972
Liabilities and Equity	(5,952,150)		(5,952,150)
Discontinued Operation, Tax Effect of Discontinued Operation	59		70
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	(610)		(621)
Net income	59,876		79,091
Accounting Standards Update 2014-09 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Impact of New Accounting Principle, Comprehensive income	(4,200)		(11,000)
Product [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	(495,608)	(355,001)	(943,216)	(688,715)
Cost of Goods and Services Sold	(229,723)	(173,040)	(449,979)	(336,064)
Product [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	(9,178)		(22,364)
Cost of Goods and Services Sold	(3,566)		(7,682)
Product [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	(486,430)		(920,852)
Cost of Goods and Services Sold	(226,157)		(442,297)
Service [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	(207,754)	(191,961)	(404,118)	(372,362)
Cost of Goods and Services Sold	(133,499)	$ (116,320)	(264,993)	$ (227,655)
Service [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0		0
Cost of Goods and Services Sold	0		0
Service [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	(207,754)		(404,118)
Cost of Goods and Services Sold	$ (133,499)		$ (264,993)

Business Combinations (Narrativ

Business Combinations (Narrative) (Details)	3 Months Ended			6 Months Ended		12 Months Ended
	Jul. 01, 2018USD ($)	Apr. 01, 2018USD ($)	Jul. 02, 2017USD ($)$ / shares	Jul. 01, 2018USD ($)	Jul. 02, 2017USD ($)$ / shares	Dec. 31, 2017USD ($)employees	Jan. 03, 2016USD ($)	Apr. 02, 2017USD ($)	Jan. 01, 2017USD ($)
Business Acquisition [Line Items]
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions				1 year
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 85,000,000			$ 85,000,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	74,093,000	$ 65,445,000	$ 64,076,000	$ 74,093,000	$ 64,076,000	$ 65,328,000		$ 63,978,000	$ 63,201,000
Business Combination, Contingent Consideration Arrangements, Maximum Period				1 year 3 months
Business Combination, Contingent Consideration Arrangements, Weighted Average Period				6 months
Total transaction costs	1,600,000		3,700,000	$ 4,200,000	6,300,000
Business Combination, Contingent Consideration Arrangements, Description				Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash.
Goodwill	2,940,825,000			$ 2,940,825,000		3,002,198,000
Business Combination, Contingent Consideration, Liability, Current	67,500,000			67,500,000		52,200,000
Business Combination, Contingent Consideration, Liability, Noncurrent	6,600,000			$ 6,600,000		13,100,000
EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue			625,525,000		1,206,079,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual						13,500,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual						$ (1,000,000)
Business Acquisition, Percentage of Voting Interests Acquired						99.98%
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments						$ 0
Business Combination, Consideration Transferred						1,388,762,000
Cash Acquired						(25,018,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets						121,174,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment						129,964,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets						$ 49,944,000
Entity Number of Employees | employees						2,400
Cash paid to the shareholders						$ 1,413,780,000
Business Combination, Consideration Transferred, Liabilities Incurred						0
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life				16 years 1 month
Goodwill	582,692,000			$ 582,692,000
Intangible Assets, Gross (Excluding Goodwill)	907,400,000			907,400,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt						61,357,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net						1,388,762,000
Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax			$ 53,024,000		$ 78,617,000
Business Acquisition, Pro Forma Earnings Per Share, Basic | $ / shares			$ 0.48		$ 0.72
Business Acquisition, Pro Forma Earnings Per Share, Diluted | $ / shares			$ 0.48		$ 0.71
Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments				101,000
Business Combination, Consideration Transferred				38,525,000
Cash Acquired				370,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	2,750,000			2,750,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	311,000			311,000
Cash paid to the shareholders				34,942,000
Business Combination, Consideration Transferred, Liabilities Incurred				$ 2,354,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life				12 years
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value				$ 1,700,000
Goodwill	19,793,000			19,793,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	38,525,000			38,525,000
Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments						93,000
Business Combination, Consideration Transferred						139,602,000
Cash Acquired						2,439,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets						16,268,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment						11,356,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets						1,691,000
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments						142,041,000
Cash paid to the shareholders						140,861,000
Business Combination, Consideration Transferred, Liabilities Incurred						1,273,000
Goodwill						75,250,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt						0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net						139,602,000
Vanadis Diagnostics AB [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High							$ 93,000,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value				72,416,000			$ 56,878,000
Tulip Diagnostics Private Limited [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments						$ 127,280,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life						11 years 9 months
Euroimmun [Member]
Business Acquisition [Line Items]
Goodwill, Purchase Accounting Adjustments	(8,061,000)
Business Combination, Increase (Decrease) in Intangible Assets	10,000,000
Business Combination, Increase (Decrease) in Liabilities Assumed	1,000,000
Business Combination, Increase (Decrease) in Deferred Tax Liabilities	(2,901,000)
Shanghai Spectrum Instruments Co., Ltd. [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value				1,678,000
Fiscal Year 2017 Other Acquisitions, Excluding Tulip [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments						$ 14,700,000
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,608,452,000			1,608,452,000		1,657,963,000
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	1,332,373,000			1,332,373,000		1,344,235,000
Core Technology [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						160,000,000
Core Technology [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	15,957,000			15,957,000
Core Technology [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						12,400,000
Customer Relationships [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	710,000,000			710,000,000
Customer Relationships [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	5,100,000			5,100,000
Customer Relationships [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						43,700,000
Trade Names [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						36,000,000
Trade Names [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	610,000			610,000
Trade Names [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						3,000,000
In-process Research and Development [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						1,400,000
In-process Research and Development [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						0
Euro Member Countries, Euro | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments						1,200,000,000
India, Rupees | Tulip Diagnostics Private Limited [Member]
Business Acquisition [Line Items]
Business Combination, Payment of Stay Bonus		716,286,000
Business Combination, Remaining Stay Bonus To Be Paid	803,600,000			803,600,000
Business Combination, Stay Bonus Which May Be Paid, Maximum						1,600,000,000
United States of America, Dollars | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments						1,413,780,000
United States of America, Dollars | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments				38,895,000
United States of America, Dollars | Tulip Diagnostics Private Limited [Member]
Business Acquisition [Line Items]
Business Combination, Payment of Stay Bonus		$ 11,254,000
Business Combination, Remaining Stay Bonus To Be Paid	11,700,000			11,700,000
Business Combination, Stay Bonus Which May Be Paid, Maximum						25,200,000
United States of America, Dollars | Shanghai Spectrum Instruments Co., Ltd. [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments				15,398,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	2,000,000			2,000,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value				1,700,000
Business Combination, Additional Consideration, Liability	2,500,000			2,500,000
Business Combination, Additional Consideration, Liability, at Fair Value	$ 2,400,000			2,400,000
United States of America, Dollars | RHS Limited [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments				$ 19,442,000
Cash and Cash Equivalents [Member] | United States of America, Dollars | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments						503,780,000
Term Loan Credit Facility, 12 Months Maturity [Member] | United States of America, Dollars | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments						200,000,000
Line of Credit, Maturing August 11, 2021 [Member] | United States of America, Dollars | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments						$ 710,000,000

Business Combinations (Fair Val

Business Combinations (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jul. 01, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill	$ 2,940,825,000	$ 3,002,198,000
EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid		1,413,780,000
Business Combination, Consideration Transferred, Liabilities Incurred		0
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments		0
Cash Acquired		(25,018,000)
Business Combination, Consideration Transferred		1,388,762,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets		121,174,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		129,964,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets		49,944,000
Goodwill	582,692,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(253,354,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	(87,701,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		1,388,762,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt		(61,357,000)
Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid		140,861,000
Business Combination, Consideration Transferred, Liabilities Incurred		1,273,000
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments		93,000
Cash Acquired		2,439,000
Business Combination, Consideration Transferred		139,602,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets		16,268,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		11,356,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets		1,691,000
Goodwill		75,250,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total		(15,735,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities		(8,328,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		139,602,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt		0
Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid	34,942,000
Business Combination, Consideration Transferred, Liabilities Incurred	2,354,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	(1,700,000)
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments	101,000
Cash Acquired	370,000
Business Combination, Consideration Transferred	38,525,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	2,750,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	311,000
Goodwill	19,793,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(2,523,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	(3,473,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	38,525,000
Shanghai Spectrum Instruments Co., Ltd. [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	(1,678,000)
Core Technology [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		160,000,000
Core Technology [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		12,400,000
Core Technology [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	15,957,000
Trade Names [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		36,000,000
Trade Names [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		3,000,000
Trade Names [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	610,000
Customer Relationships [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	710,000,000
Customer Relationships [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		43,700,000
Customer Relationships [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	5,100,000
In-process Research and Development [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		1,400,000
In-process Research and Development [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		0
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,608,452,000	1,657,963,000
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	1,332,373,000	$ 1,344,235,000
United States of America, Dollars | Shanghai Spectrum Instruments Co., Ltd. [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	$ (1,700,000)

Discontinued Operations (Narrat

Discontinued Operations (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Revenue	$ 0	$ 8,249	$ 0	$ 44,343
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	(610)	141,343	(621)	143,884
(Loss) income from discontinued operations before income taxes	0	(3,109)	0	650
Pre-tax gain (loss) on disposal of business unit	(551)	180,377	(551)	180,377
Discontinued Operation, Tax Effect of Discontinued Operation	59	35,925	70	37,143
Current liabilities of discontinued operations	2,165		2,165		$ 2,102
Disposal Group, Including Discontinued Operation, Costs of Goods Sold	0	8,138	0	32,933
Disposal Group, Including Discontinued Operation, General and Administrative Expense	0	1,926	0	5,869
Disposal Group, Including Discontinued Operations, Research and development expenses	0	1,294	0	4,891
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax	$ 0	$ (3,109)	$ 0	$ 650
Medical Imaging Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration					277,400
Disposal Group, Including Discontinued Operation, Working Capital Adjustment					4,200
Pre-tax gain (loss) on disposal of business unit					179,615
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation					43,131
Discontinued Operation, Period of Continuing Involvement after Disposal			12 months
Suzhou PerkinElmer Medical Laboratory Co. Ltd [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration					2,300
Pre-tax gain (loss) on disposal of business unit					$ (1,108)

Restructuring and Lease Charg50

Restructuring and Lease Charges, Net (Narrative) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jul. 01, 2018	Dec. 31, 2017
Restructuring Cost and Reserve [Line Items]
Accrued restructuring and integration costs	$ 12,232	$ 13,969
Accrued expenses and other current liabilities	7,443	8,759
Restructuring Reserve, Noncurrent	1,900	2,300
Restructuring Reserve, Current other	2,900	$ 2,900
Restructuring Reserve, Accrual Adjustment	$ 580

Restructuring and Lease Charg51

Restructuring and Lease Charges, Net (Schedule of Initial Charges) (Details) $ in Thousands	3 Months Ended				6 Months Ended
	Apr. 01, 2018USD ($)employees	Dec. 31, 2017USD ($)employees	Oct. 01, 2017USD ($)employees	Apr. 02, 2017USD ($)employees	Jul. 01, 2018USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve		$ 13,969			$ 12,232
Restructuring and contract termination charges, net					5,998
Restructuring Reserve, Accrual Adjustment					580
Restructuring reserve Settled with Cash and Translation Adjustment					(8,315)
Q1 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees	47
Restructuring and contract termination charges, net	$ 5,998
Q4 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees		29
Restructuring and contract termination charges, net		$ 1,935
Q3 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees			27
Restructuring and contract termination charges, net			$ 2,342
Q1 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees				90
Restructuring and contract termination charges, net				$ 6,697
Employee Severance [Member] | Q1 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve		0			2,392
Restructuring and contract termination charges, net					5,998
Restructuring Reserve, Accrual Adjustment					0
Restructuring reserve Settled with Cash and Translation Adjustment					(3,606)
Employee Severance [Member] | Q4 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve		1,919			603
Restructuring and contract termination charges, net					0
Restructuring Reserve, Accrual Adjustment					0
Restructuring reserve Settled with Cash and Translation Adjustment					(1,316)
Employee Severance [Member] | Q3 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve		2,072			1,209
Restructuring and contract termination charges, net					0
Restructuring Reserve, Accrual Adjustment					0
Restructuring reserve Settled with Cash and Translation Adjustment					(863)
Employee Severance [Member] | Q1 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve		2,498			1,425
Restructuring and contract termination charges, net					0
Restructuring Reserve, Accrual Adjustment					0
Restructuring reserve Settled with Cash and Translation Adjustment					1,073
Facility Closing [Member] | Q1 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve		33			11
Restructuring and contract termination charges, net					0
Restructuring Reserve, Accrual Adjustment					0
Restructuring reserve Settled with Cash and Translation Adjustment					$ (22)
Diagnostics [Member] | Employee Severance [Member] | Q1 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	902
Diagnostics [Member] | Employee Severance [Member] | Q4 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net		255
Diagnostics [Member] | Employee Severance [Member] | Q3 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net			1,021
Diagnostics [Member] | Employee Severance [Member] | Q1 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net				1,631
Diagnostics [Member] | Facility Closing [Member] | Q1 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	0
Diagnostics [Member] | Facility Closing [Member] | Q4 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net		0
Diagnostics [Member] | Facility Closing [Member] | Q3 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net			0
Diagnostics [Member] | Facility Closing [Member] | Q1 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net				33
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q1 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	5,096
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q4 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net		1,680
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q3 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net			1,321
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q1 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net				5,000
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q1 2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	$ 0
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q4 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net		$ 0
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q3 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net			$ 0
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q1 2017 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net				$ 33

Restructuring and Lease Charg52

Restructuring and Lease Charges, Net (Schedule of Restructuring Plan Activity) (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Dec. 31, 2017	Oct. 01, 2017	Apr. 02, 2017	Jul. 01, 2018
Restructuring Reserve [Roll Forward]
Balance at beginning of period				$ 13,969
Restructuring and contract termination charges, net				5,998
Restructuring Reserve, Accrual Adjustment				580
Restructuring reserve Settled with Cash and Translation Adjustment				(8,315)
Balance at end of period	$ 13,969			12,232
Employee Severance and Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period				10,921
Restructuring and contract termination charges, net				5,998
Restructuring Reserve, Accrual Adjustment				353
Restructuring reserve Settled with Cash and Translation Adjustment				(8,315)
Balance at end of period	10,921			8,957
Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period				3,048
Restructuring and contract termination charges, net				0
Restructuring Reserve, Accrual Adjustment				227
Restructuring reserve Settled with Cash and Translation Adjustment				0
Balance at end of period	3,048			3,275
Q4 2017 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	1,935
Q4 2017 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period				1,919
Restructuring and contract termination charges, net				0
Restructuring Reserve, Accrual Adjustment				0
Restructuring reserve Settled with Cash and Translation Adjustment				(1,316)
Balance at end of period	1,919			603
Q3 2017 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		$ 2,342
Q3 2017 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period				2,072
Restructuring and contract termination charges, net				0
Restructuring Reserve, Accrual Adjustment				0
Restructuring reserve Settled with Cash and Translation Adjustment				(863)
Balance at end of period	2,072			1,209
Q1 2017 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			$ 6,697
Q1 2017 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period				2,498
Restructuring and contract termination charges, net				0
Restructuring Reserve, Accrual Adjustment				0
Restructuring reserve Settled with Cash and Translation Adjustment				1,073
Balance at end of period	2,498			1,425
Q1 2017 Restructuring Plan [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period				33
Restructuring and contract termination charges, net				0
Restructuring Reserve, Accrual Adjustment				0
Restructuring reserve Settled with Cash and Translation Adjustment				(22)
Balance at end of period	33			11
Previous restructuring and integration plans [Member] | Employee Severance and Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period				4,399
Restructuring and contract termination charges, net				0
Restructuring Reserve, Accrual Adjustment				353
Restructuring reserve Settled with Cash and Translation Adjustment				(1,435)
Balance at end of period	4,399			3,317
Diagnostics [Member] | Q4 2017 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	255
Diagnostics [Member] | Q4 2017 Restructuring Plan [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	0
Diagnostics [Member] | Q3 2017 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		1,021
Diagnostics [Member] | Q3 2017 Restructuring Plan [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		0
Diagnostics [Member] | Q1 2017 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			1,631
Diagnostics [Member] | Q1 2017 Restructuring Plan [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			33
Discovery & Analytical Solutions [Member] | Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net				$ 227
Discovery & Analytical Solutions [Member] | Q4 2017 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	1,680
Discovery & Analytical Solutions [Member] | Q4 2017 Restructuring Plan [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net	$ 0
Discovery & Analytical Solutions [Member] | Q3 2017 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		1,321
Discovery & Analytical Solutions [Member] | Q3 2017 Restructuring Plan [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net		$ 0
Discovery & Analytical Solutions [Member] | Q1 2017 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			5,000
Discovery & Analytical Solutions [Member] | Q1 2017 Restructuring Plan [Member] | Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Restructuring and contract termination charges, net			$ 33

Interest and Other Expense (I53

Interest and Other Expense (Income), Net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Other Income and Expenses [Abstract]
Interest income	$ (173)	$ (490)	$ (438)	$ (710)
Interest expense	16,411	10,672	34,061	21,536
Gain on disposition of businesses and assets, net	0	301	0	301
Other expense, net	118	(7,092)	(5,837)	(7,908)
Total interest and other expense, net	16,356	3,391	27,786	13,219
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	(10,300)	(4,100)	12,300	(1,700)
Foreign Currency Transaction Gain (Loss), before Tax	(12,900)	1,200	13,100	2,700
Defined Benefit Plan, Other Cost (Credit)	$ (2,500)	$ (1,800)	$ (5,000)	$ (3,600)

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Jul. 01, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 128,927	$ 122,100
Work in progress	21,376	18,452
Finished goods	216,658	211,123
Total inventories, net	$ 366,961	$ 351,675

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017	Dec. 31, 2017
Income Tax Contingency [Line Items]
Provision for income taxes	$ 7,035	$ 8,066	$ 9,505	$ 11,987
Unrecognized tax benefits, gross	30,500		30,500
Uncertain tax benefits if recognized that could affect the continuing operations effective tax rate	28,800		28,800
Uncertain tax positions including accrued interest, net of tax benefits and penalties, to be resolved within the next year	6,100		$ 6,100
Open Tax Years by Major Tax Jurisdiction, Begin Date			2,010
Tax Adjustments, Settlements, and Unusual Provisions			$ (1,600)	(4,900)
Discontinued Operation, Tax Effect of Discontinued Operation	59	35,925	70	37,143
Income Tax Expense (Benefit), Intraperiod Tax Allocation	$ 7,094	$ 43,991	9,575	49,130
Excess Income Tax Benefit on Stock Compensation			(1,900)	$ (3,400)
2017 Tax Cuts and Jobs Act [Member]
Income Tax Contingency [Line Items]
Tax Adjustments, Settlements, and Unusual Provisions			$ 1,500		$ 21,500
Income Tax Expense on Repatriated Earnings					$ 85,000

Debt (Details)

Debt (Details) € in Millions	Apr. 11, 2018USD ($)	Jul. 19, 2016EUR (€)	Oct. 25, 2011USD ($)	Jul. 01, 2018USD ($)	Dec. 30, 2012USD ($)	Jul. 01, 2018EUR (€)	Dec. 31, 2017USD ($)	Dec. 31, 2017EUR (€)
Other Secured Bank Loan [Member]
Interest rate terms under amended senior unsecured revolving credit facility				The secured bank loan of $0.3 million bears a fixed annual interest rate of 1.95% and is repaid in monthly installments until 2027.
Secured Debt | €						€ 0.3
Debt Instrument, Interest Rate, Stated Percentage				1.95%		1.95%
Line of Credit, Maturing August 11, 2021 [Member]
Line of Credit Facility, Maximum Borrowing Capacity				$ 1,000,000,000
Unsecured revolving credit facility, expiry date				Aug. 11, 2021
Letters of credit issued and outstanding				$ 11,400,000
Line of Credit Facility, Remaining Borrowing Capacity				488,600,000
Aggregate borrowings under the amended facility				500,000,000			$ 625,000,000
Unamortized Debt Issuance Expense				$ 2,900,000			3,300,000
Term Loan Credit Facility, 12 Months Maturity [Member]
Interest rate terms under amended senior unsecured revolving credit facility				The interest rates under the senior unsecured term loan credit facility are based on the Eurocurrency rate or the base rate at the time of the borrowing, plus a margin. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) an adjusted one-month Libor plus 1.00%.
Term Loan Credit Facility, Maximum Borrowing Capacity				$ 200,000,000
Short-term Debt, Terms				twelve months
Short-term Debt, Maximum Amount Outstanding During Period				$ 200,000,000
2021 Notes [Member]
Interest rate terms under amended senior unsecured revolving credit facility				Interest on the November 2021 Notes is payable semi-annually on May 15th and November 15th each year. Prior to August 15, 2021 (three months prior to their maturity date), the Company may redeem the November 2021 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the November 2021 Notes to be redeemed, plus accrued and unpaid interest, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the November 2021 Notes being redeemed, discounted on a semi-annual basis, at the Treasury Rate plus 45 basis points, plus accrued and unpaid interest.
Debt Instrument, Interest Rate, Stated Percentage			5.00%
Unsecured senior notes, face value			$ 500,000,000
Gross proceeds from the issuance of debt instrument			$ 493,600,000
Senior unsecured notes issuance as percentage of principal amount			99.372%
Debt Instrument, Unamortized Discount			$ 3,100,000	$ 1,300,000			1,400,000
Debt instrument maturity date			Nov. 25, 2021
Percentage of redemption of senior notes on or after August 15, 2021			100.00%
Percentage of redemption upon a change of control and a contemporaneous downgrade of the Notes			101.00%
Unamortized Debt Issuance Expense				$ 1,800,000			2,000,000
2021 Notes [Member] | Treasury Rate [Member]
Basis spread on variable rate				0.45%
Financing Lease Obligations [Member]
Initial Fair Value of Other Long-term Debt Related to Financing Lease Obligations					$ 29,300,000
Additional Financing Lease Obligations, funded by lessors					$ 11,500,000
Other Long-term Debt, Current				$ 1,500,000			1,400,000
Other Long-term Debt, Noncurrent				33,800,000			34,500,000
1.875 Percent Ten Year Senior Unsecured Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage		1.875%
Unsecured senior notes, face value | €		€ 500
Gross proceeds from the issuance of debt instrument | €		€ 492.3
Senior unsecured notes issuance as percentage of principal amount		99.118%
Debt Instrument, Unamortized Discount		€ 4.4		4,300,000			4,700,000
Debt instrument maturity date		Jul. 19, 2026
Percentage of redemption upon a change of control and a contemporaneous downgrade of the Notes		101.00%
Unamortized Debt Issuance Expense				$ 4,000,000			$ 4,300,000
0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Interest rate terms under amended senior unsecured revolving credit facility				Interest on the April 2021 Notes is payable annually on April 9th each year.
Debt Instrument, Interest Rate, Stated Percentage	0.60%
Unsecured senior notes, face value	$ 300,000,000
Gross proceeds from the issuance of debt instrument	$ 298,700,000
Senior unsecured notes issuance as percentage of principal amount	99.95%
Debt Instrument, Unamortized Discount	$ 200,000			$ 200,000
Debt instrument maturity date	Apr. 9, 2021
Percentage of redemption upon a change of control and a contemporaneous downgrade of the Notes	101.00%
Unamortized Debt Issuance Expense				$ 2,700,000
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | Treasury Rate [Member]
Basis spread on variable rate				0.15%
Other Debt Facilities - EUROIMMUN [Member]
Interest rate terms under amended senior unsecured revolving credit facility				The bank loans in the aggregate amount of $42.8 million bear fixed interest rates between 1.1% and 7.9% and bank loans in the aggregate amount of $3.6 million bear variable interest rates based on the Euribor rate plus a margin between 1.3% and 1.5%.
Long-term Debt, Percentage Bearing Variable Interest, Amount | €						€ 3.6
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €						45.3
Other Unsecured Revolving Debt Facilities [Member]
Other Unsecured Revolving Credit Facilities				$ 2,200,000
Interest rate terms under amended senior unsecured revolving credit facility				The unsecured revolving debt facilities bear fixed interest rates between 0.05% and 1.95% and will mature in 2018.
Unsecured Revolving Credit Facility [Member] | Base Rate Option Two [Member]
Description of variable rate basis				Federal Funds
Unsecured Revolving Credit Facility [Member] | Eurocurrency Rate [Member]
Description of variable rate basis				Eurocurrency
Unsecured Revolving Credit Facility [Member] | Line of Credit, Maturing August 11, 2021 [Member]
Interest rate terms under amended senior unsecured revolving credit facility				The interest rates under the senior unsecured revolving credit facility are based on the Eurocurrency rate or the base rate at the time of borrowing, plus a margin. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) an adjusted one-month Libor plus 1.00%. The Eurocurrency margin as of July 1, 2018 was 110 basis points.
Weighted average interest rates under amended senior unsecured revolving credit facility				The weighted average Eurocurrency interest rate as of July 1, 2018 was 2.12%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 3.22%,
Unsecured Revolving Credit Facility [Member] | Line of Credit, Maturing August 11, 2021 [Member] | Base Rate Option Two [Member]
Basis spread on variable rate				0.50%
Unsecured Revolving Credit Facility [Member] | Line of Credit, Maturing August 11, 2021 [Member] | Base Rate Option Three [Member]
Basis spread on variable rate				1.00%
Unsecured Revolving Credit Facility [Member] | Line of Credit, Maturing August 11, 2021 [Member] | Eurocurrency Rate [Member]
Basis spread on variable rate				1.10%
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member]
Unsecured Debt | €						40.8
Secured Debt | €						5.6
Other Long-term Debt | €						46.4		€ 57.2
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €						42.8
Euro Member Countries, Euro | Other Debt Facilities - EUROIMMUN [Member]
Other Long-term Debt | €						€ 39.8		€ 47.6
Minimum [Member] | Other Debt Facilities - EUROIMMUN [Member]
Debt Instrument, Interest Rate, Stated Percentage				0.10%		0.10%
Minimum [Member] | Other Debt Facilities - EUROIMMUN [Member] | Euribor Rate [Member]
Basis spread on variable rate				1.30%
Minimum [Member] | Other Unsecured Revolving Debt Facilities [Member]
Debt Instrument, Interest Rate, Stated Percentage				0.05%		0.05%
Minimum [Member] | United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member]
Debt Instrument, Interest Rate, Stated Percentage				1.10%		1.10%
Maximum [Member] | Other Debt Facilities - EUROIMMUN [Member]
Debt Instrument, Interest Rate, Stated Percentage							7.90%	7.90%
Maximum [Member] | Other Debt Facilities - EUROIMMUN [Member] | Euribor Rate [Member]
Basis spread on variable rate				1.50%
Maximum [Member] | Other Unsecured Revolving Debt Facilities [Member]
Debt Instrument, Interest Rate, Stated Percentage				1.95%		1.95%
Maximum [Member] | United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member]
Debt Instrument, Interest Rate, Stated Percentage				7.90%		7.90%
Significant Other Observable Inputs (Level 2) [Member] | Line of Credit, Maturing August 11, 2021 [Member]
Long-term Debt				$ 497,100,000			$ 621,700,000
Significant Other Observable Inputs (Level 2) [Member] | 2021 Notes [Member]
Long-term Debt				496,900,000			496,600,000
Significant Other Observable Inputs (Level 2) [Member] | Financing Lease Obligations [Member]
Other Long-term Debt				35,300,000			35,900,000
Significant Other Observable Inputs (Level 2) [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Long-term Debt				575,100,000			$ 591,700,000
Significant Other Observable Inputs (Level 2) [Member] | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Long-term Debt				$ 347,200,000
Significant Other Observable Inputs (Level 2) [Member] | Other Debt Facilities - EUROIMMUN [Member]
Other Long-term Debt | €						€ 48.9		€ 60.2

Earnings Per Share (Schedule of

Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Earnings Per Share [Abstract]
Number of common shares-basic	110,477	109,894	110,386	109,681
Effect of dilutive securities, Stock options	786	668	824	636
Effect of dilutive securities, Restricted stock	189	200	181	167
Number of common shares-diluted	111,452	110,762	111,391	110,484
Number of potentially dilutive securities excluded from calculation due to antidilutive impact	346	457	339	558

Industry Segment Information In

Industry Segment Information Industry Segment Information Narrative (Details)	6 Months Ended
	Jul. 01, 2018segments
Segment Reporting Information [Line Items]
Number of Operating Segment	2

Industry Segment Information (S

Industry Segment Information (Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 703,362	$ 546,962	$ 1,347,334	$ 1,061,077
Operating income (loss) from continuing operations	88,064	74,183	127,999	123,994
Interest and other expense, net	16,356	3,391	27,786	13,219
Income from continuing operations before income taxes	71,708	70,792	100,213	110,775
Corporate [Member]
Segment Reporting Information [Line Items]
Operating income (loss) from continuing operations	(15,381)	(13,888)	(30,037)	(27,015)
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	272,734	163,834	520,181	316,189
Operating income (loss) from continuing operations	38,780	36,947	57,174	69,663
Discovery & Analytical Solutions [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	430,628	383,128	827,153	744,888
Operating income (loss) from continuing operations	64,665	51,124	100,862	81,346
Product [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	495,608	355,001	943,216	688,715
Product [Member] | Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	232,283	127,711	442,196	246,265
Product [Member] | Discovery & Analytical Solutions [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	263,325	227,290	501,020	442,450
Service [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	207,754	191,961	404,118	372,362
Service [Member] | Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	40,451	36,123	77,985	69,924
Service [Member] | Discovery & Analytical Solutions [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 167,303	$ 155,838	$ 326,133	$ 302,438

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended							6 Months Ended	9 Months Ended
	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 31, 2017	Oct. 01, 2017	Jul. 02, 2017	Jul. 01, 2018	Sep. 30, 2018	Jul. 23, 2018	Jul. 27, 2016
Schedule of Shareholders' Equity [Line Items]
Stock repurchase program, number of shares authorized to be repurchased											8,000,000
Stock repurchase program, number of shares remained available for repurchase			8,000,000					8,000,000
Repurchased Common Shares For Activity Pursuant to Equity Incentive Plans			1,250					59,699
Aggregate Cost of Repurchased Common Shares for Activity Pursuant to Equity Incentive Plans			$ 0.1					$ 4.6
Cash dividends (per share)			$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07
Dividends Payable, Amount			$ 7.7					$ 7.7
Dividends Payable, Date Declared			Apr. 26, 2018
Dividends Payable, Date to be Paid								Aug. 10, 2018
Subsequent Event [Member]
Schedule of Shareholders' Equity [Line Items]
Stock Repurchase Program, Authorized Amount										$ 250
Cash dividends (per share)		$ 0.07
Dividends Payable, Date Declared									Jul. 23, 2018
Dividends Payable, Date to be Paid	Nov. 10, 2018

Stockholders' Equity (Component

Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Thousands	Jul. 01, 2018	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Foreign currency translation adjustments, net of income taxes	$ (130,675)	$ (46,582)
Unrecognized losses and prior service costs, net of income taxes	322	322
Unrealized net losses on securities, net of income taxes	(213)	(258)
Accumulated other comprehensive loss	$ (130,566)	$ (46,518)

Stock Plans (Narrative) (Detail

Stock Plans (Narrative) (Details) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018USD ($)$ / sharesshares	Jul. 02, 2017USD ($)$ / shares	Jul. 01, 2018USD ($)plan$ / sharesshares	Jul. 02, 2017USD ($)$ / sharesshares	Dec. 31, 2017shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Former Stock-based Compensation Plans | plan			1
Total income tax benefit recognized for stock-based compensation	$ 1,600	$ 5,100	$ 4,500	$ 8,000
Stock-based compensation costs capitalized as part of inventory			400
Proceeds from issuance of common stock under stock plans			8,348	13,223
Total pre-tax stock-based compensation expense	$ 6,816	$ 6,841	$ 12,148	$ 11,767
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of options | $ / shares	$ 17.30	$ 13.27	$ 17.49	$ 11.74
Total intrinsic value of options exercised	$ 700	$ 9,100	$ 6,400	$ 12,200
Proceeds from issuance of common stock under stock plans			8,300	13,200
Total pre-tax stock-based compensation expense	1,300	1,200	2,600	2,400
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	9,200		$ 9,200
Weighted-average period for recognition of unrecognized compensation cost, years			2 years 1 month
Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	3,200	3,000	$ 5,600	5,400
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	$ 21,600		$ 21,600
Weighted-average period for recognition of unrecognized compensation cost, years			1 year 8 months 15 days
Awards/units outstanding | shares	497,000		497,000		496,000
Number of Shares, Granted | shares			194,000
Weighted-average grant-date fair value of stock granted (per share) | $ / shares			$ 75.37
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares			12,000
Fair value of restricted stock awards vested	$ 700	1,500	$ 9,000	9,300
Performance Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	$ 1,000	1,700	$ 2,300	2,800
Awards/units outstanding | shares	201,762		201,762
Number of Shares, Granted | shares			37,281
Weighted-average grant-date fair value of stock granted (per share) | $ / shares			$ 73.23
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares			0
Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent	$ 8,600		$ 8,600
Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense			$ 800	$ 700
Number of Shares, Granted | shares			1,386
Weighted-average grant-date fair value of stock granted (per share) | $ / shares			$ 72.17
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under plan | shares	5,000,000		5,000,000
Number of Shares, Granted | shares			21,321	18,483
Weighted-average grant-date fair value of stock granted (per share) | $ / shares			$ 69.57	$ 64.73
Shares available for grant under employee stock purchase plan | shares	800,000		800,000
Performance Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	$ 500	$ 200	$ 900	$ 500
Awards/units outstanding | shares	93,470		93,470
Number of Shares, Granted | shares			39,133
Weighted-average grant-date fair value of stock granted (per share) | $ / shares			$ 80.31
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares				0
2009 Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under plan | shares	10,000,000		10,000,000

Stock Plans (Summary of Total C

Stock Plans (Summary of Total Compensation Recognized Related to Outstanding Stock Options) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	$ 6,816	$ 6,841	$ 12,148	$ 11,767
Cost of sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	358	281	663	541
Research and development expenses [Member ]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	386	377	694	704
Selling, general and administrative and other expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	$ 6,072	$ 6,183	$ 10,791	$ 10,522

Stock Plans (Weighted-Average A

Stock Plans (Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model) (Details)	6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk-free interest rate	2.90%	1.80%
Expected dividend yield	0.40%	0.50%
Expected lives, years	5 years	5 years
Expected stock volatility	20.70%	22.40%

Stock Plans (Summary of Stock O

Stock Plans (Summary of Stock Option Activity) (Details) $ / shares in Units, shares in Thousands, $ in Millions	6 Months Ended
	Jul. 01, 2018USD ($)$ / sharesshares
Stock option activity
Number of Shares, Outstanding at beginning of period | shares	2,154
Number of Shares, Granted | shares	342
Number of Shares, Exercised | shares	(194)
Number of Shares, Forfeited | shares	(10)
Number of Shares, Outstanding at end of period | shares	2,292
Number of Shares, Exercisable at end of period | shares	1,464
Weighted-Average Price, Outstanding at beginning of period | $ / shares	$ 42.77
Weighted-Average Price, Granted | $ / shares	77.61
Weighted-Average Price, Exercised | $ / shares	42.98
Weighted-Average Price, Forfeited | $ / shares	59.61
Weighted-Average Price, Outstanding at end of period | $ / shares	47.88
Weighted-Average Price, Exercisable at end of period | $ / shares	$ 40.05
Weighted-Average Remaining Contractual Term in Years, Outstanding at end of period	3 years 11 months
Weighted-Average Remaining Contractual Term in Years, Exercisable at end of period	2 years 11 months
Total Intrinsic Value, Outstanding at end of period | $	$ 58.1
Total Intrinsic Value, Exercisable at end of period | $	$ 48.6

Stock Plans (Summary of Restric

Stock Plans (Summary of Restricted Stock Award Activity) (Details) - Restricted Stock Awards [Member] shares in Thousands	6 Months Ended
	Jul. 01, 2018$ / sharesshares
Restricted stock award activity
Number of Shares, Nonvested at beginning of period | shares	496
Number of Shares, Granted | shares	194
Number of Shares, Vested | shares	(181)
Number of Shares, Forfeited | shares	(12)
Number of Shares, Nonvested at end of period | shares	497
Weighted-Average Grant-Date Fair Value, Nonvested at beginning of period | $ / shares	$ 50.30
Weighted-Average Grant-Date Fair Value, Granted | $ / shares	75.37
Weighted-Average Grant-Date Fair Value, Vested | $ / shares	49.54
Weighted-Average Grant-Date Fair Value, Forfeited | $ / shares	55.62
Weighted-Average Grant-Date Fair Value, Nonvested at end of period | $ / shares	$ 60.26

Goodwill and Intangible Asset67

Goodwill and Intangible Assets, Net (Narrative) (Details) - USD ($) $ in Thousands	Jan. 01, 2018	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017	Dec. 31, 2017
Goodwill and Intangible Assets Net [Line Items]
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount	20.00%
Change in any one of the input assumptions for the various reporting units	10.00%
Goodwill		$ 2,940,825		$ 2,940,825		$ 3,002,198
Total amortization expense related to finite-lived intangible assets		32,500	$ 17,500	65,400	$ 34,600
Future Amortization Expense, Year One		68,300		68,300
Future Amortization Expense, Year Two		144,500		144,500
Future Amortization Expense, Year Three		146,900		146,900
Future Amortization Expense, Year Four		131,600		131,600
Future Amortization Expense, Year Five		119,600		119,600
Finite-Lived Intangible Assets, Net		1,200,283		1,200,283		1,276,356
Intangible assets, net		1,270,867		1,270,867		1,346,940
Minimum [Member]
Goodwill and Intangible Assets Net [Line Items]
Long-term terminal growth rates for reporting units	3.00%
Discount rates for reporting units	9.00%
Maximum [Member]
Goodwill and Intangible Assets Net [Line Items]
Long-term terminal growth rates for reporting units	5.00%
Discount rates for reporting units	15.00%
Patents [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		39,953		39,953		39,959
Less: Accumulated amortization		36,389		36,389		35,085
Finite-Lived Intangible Assets, Net		3,564		3,564		4,874
Trade Names And Trademarks [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		79,586		79,586		80,974
Less: Accumulated amortization		31,400		31,400		28,250
Finite-Lived Intangible Assets, Net		48,186		48,186		52,724
Licensing Agreements [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		51,720		51,720		53,300
Less: Accumulated amortization		44,062		44,062		42,635
Finite-Lived Intangible Assets, Net		7,658		7,658		10,665
Core Technology [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		478,499		478,499		471,740
Less: Accumulated amortization		263,080		263,080		244,916
Finite-Lived Intangible Assets, Net		215,419		215,419		226,824
Customer Relationships [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		1,126,608		1,126,608		1,141,511
Less: Accumulated amortization		276,368		276,368		242,840
Finite-Lived Intangible Assets, Net		850,240		850,240		898,671
In-process Research and Development [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		81,152		81,152		88,025
Less: Accumulated amortization		5,936		5,936		5,427
Finite-Lived Intangible Assets, Net		$ 75,216		$ 75,216		82,598
Informatics [Member]
Goodwill and Intangible Assets Net [Line Items]
Goodwill	$ 217,200
Medical Imaging Business [Member]
Goodwill and Intangible Assets Net [Line Items]
Disposal Group, Including Discontinued Operation, Consideration						$ 277,400

Goodwill and Intangible Asset68

Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) $ in Thousands	6 Months Ended
	Jul. 01, 2018USD ($)
Changes in the carrying amount of goodwill
Balance at beginning of period	$ 3,002,198
Foreign currency translation	(48,701)
Goodwill, Acquisition, Earn Outs and Other Adjustments	(12,672)
Balance at end of period	2,940,825
Diagnostics [Member]
Changes in the carrying amount of goodwill
Balance at beginning of period	1,657,963
Foreign currency translation	(26,648)
Goodwill, Acquisition, Earn Outs and Other Adjustments	(22,863)
Balance at end of period	1,608,452
Discovery & Analytical Solutions [Member]
Changes in the carrying amount of goodwill
Balance at beginning of period	1,344,235
Foreign currency translation	(22,053)
Goodwill, Acquisition, Earn Outs and Other Adjustments	10,191
Balance at end of period	$ 1,332,373

Goodwill and Intangible Asset69

Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) - USD ($) $ in Thousands	Jul. 01, 2018	Dec. 31, 2017
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	$ 1,200,283	$ 1,276,356
Intangible assets, net	1,270,867	1,346,940
Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	39,953	39,959
Less: Accumulated amortization	(36,389)	(35,085)
Net amortizable intangible assets	3,564	4,874
Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	79,586	80,974
Less: Accumulated amortization	(31,400)	(28,250)
Net amortizable intangible assets	48,186	52,724
Trade names and trademarks	70,584	70,584
Licensing Agreements [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	51,720	53,300
Less: Accumulated amortization	(44,062)	(42,635)
Net amortizable intangible assets	7,658	10,665
Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	478,499	471,740
Less: Accumulated amortization	(263,080)	(244,916)
Net amortizable intangible assets	215,419	226,824
Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	1,126,608	1,141,511
Less: Accumulated amortization	(276,368)	(242,840)
Net amortizable intangible assets	850,240	898,671
In-process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	81,152	88,025
Less: Accumulated amortization	(5,936)	(5,427)
Net amortizable intangible assets	$ 75,216	$ 82,598

Warranty Reserves (Details)

Warranty Reserves (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Warranty reserve activity
Balance beginning of period	$ 8,786	$ 8,937	$ 9,050	$ 9,012
Provision charged to income	3,515	3,391	6,685	6,380
Payments	(3,490)	(3,412)	(6,967)	(7,137)
Adjustments to previously provided warranties, net	446	(24)	336	515
Foreign currency translation and acquisitions	(314)	196	(161)	318
Balance end of period	$ 8,943	$ 9,088	$ 8,943	$ 9,088

Employee Benefit Plans (Compone

Employee Benefit Plans (Components of Net Periodic Benefit Cost (Credit)) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Defined Benefit Pension Benefits [Member]
Components of net periodic benefit cost (credit)
Service cost	$ 1,712	$ 1,222	$ 3,468	$ 2,436
Interest cost	4,057	4,133	8,161	8,260
Expected return on plan assets	(7,310)	(6,541)	(14,656)	(13,041)
Amortization of prior service	(41)	(48)	(82)	(95)
Net periodic benefit cost (credit)	(1,582)	(1,234)	(3,109)	(2,440)
Postretirement Medical Benefits [Member]
Components of net periodic benefit cost (credit)
Service cost	26	23	53	46
Interest cost	30	31	60	62
Expected return on plan assets	(313)	(278)	(627)	(557)
Amortization of prior service	0	0	0	0
Net periodic benefit cost (credit)	$ (257)	$ (224)	(514)	(449)
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Contributions by Employer			15,000
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Contributions by Employer			$ 4,400	$ 4,100

Derivatives And Hedging Activ72

Derivatives And Hedging Activities (Details) $ in Thousands, € in Millions	Apr. 11, 2018USD ($)	Jul. 01, 2018USD ($)	Apr. 01, 2018USD ($)	Jul. 02, 2017USD ($)	Jul. 01, 2018USD ($)	Jul. 02, 2017USD ($)	Jul. 01, 2018EUR (€)	Apr. 27, 2018EUR (€)	Dec. 31, 2017USD ($)	Dec. 31, 2017EUR (€)	Jul. 02, 2017EUR (€)
Derivative [Line Items]
Company's business conducted outside United States					70.00%
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax					$ 2,600
Payments for Hedge, Financing Activities					32,711
Payments for (Proceeds from) Hedge, Financing Activities					32,711	$ 4,314
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net		$ 0			0
Foreign Currency Transaction Gain (Loss), before Tax		(12,900)		$ 1,200	$ 13,100	2,700
European And Asian Currencies [Member]
Derivative [Line Items]
Maximum maturity period for foreign exchange contracts, in months					12 months
Duration Of Foreign Currency Derivatives					30 days
Fair Value Hedging [Member]
Derivative [Line Items]
Notional Amount of Cash Flow Hedge Instruments		147,600		128,600	$ 147,600	128,600			$ 212,100
Notional Amount of Euro Derivatives [Member]
Derivative [Line Items]
Notional Amount of Cash Flow Hedge Instruments | €							€ 49.7	€ 298.7		€ 57.2	€ 23.5
Notional Amount of US Dollar Derivatives [Member] | Cash Flow Hedging [Member]
Derivative [Line Items]
Notional Amount of Cash Flow Hedge Instruments		50,800		$ 133,300	50,800	$ 133,300			$ 1,253,000
Net Investment Hedging [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments					135,600
Unrealized Gain (Loss) on Net Investment Hedge in AOCI		$ (4,800)	$ (2,100)		(6,900)
Net Investment Hedging [Member] | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments	$ 298,700				298,700
Unrealized Gain (Loss) on Net Investment Hedge in AOCI					$ (20,800)

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) $ in Thousands, € in Millions

6 Months Ended

12 Months Ended

Jul. 01, 2018USD ($)

Jan. 03, 2016USD ($)

Jul. 01, 2018EUR (€)

Apr. 11, 2018USD ($)

Apr. 01, 2018USD ($)

Dec. 31, 2017USD ($)

Dec. 31, 2017EUR (€)

Jul. 02, 2017USD ($)

Apr. 02, 2017USD ($)

Jan. 01, 2017USD ($)

Jul. 19, 2016EUR (€)

Oct. 25, 2011USD ($)

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

$ 85,000

Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value

$ 74,093

$ 65,445

$ 65,328

$ 64,076

$ 63,978

$ 63,201

Business Combination, Contingent Consideration Arrangements, Description

Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash.

Business Combination, Contingent Consideration Arrangements, Maximum Period

1 year 3 months

Business Combination, Contingent Consideration Arrangements, Weighted Average Period

6 months

2021 Notes [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Unamortized Debt Issuance Expense

$ 1,800

2,000

Unsecured senior notes, face value

$ 500,000

Debt Instrument, Unamortized Discount

(1,300)

(1,400)

$ (3,100)

Unsecured senior notes, fair value

521,000

536,600

Line of Credit, Maturing August 11, 2021 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

1,000,000

Revolving credit facility outstanding balance

500,000

625,000

Unamortized Debt Issuance Expense

2,900

3,300

1.875 Percent Ten Year Senior Unsecured Notes [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Unamortized Debt Issuance Expense

4,000

4,300

Unsecured senior notes, face value | €

€ 500

Debt Instrument, Unamortized Discount

(4,300)

(4,700)

€ (4.4)

1.875 Percent Ten Year Senior Unsecured Notes [Member] | Euro Member Countries, Euro

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Unsecured senior notes, fair value

506,600

508,900

0.6 Percent Senior Unsecured Notes due in April 2021 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Unamortized Debt Issuance Expense

2,700

Unsecured senior notes, face value

$ 300,000

Debt Instrument, Unamortized Discount

(200)

$ (200)

Unsecured senior notes, fair value

301,900

Other Debt Facilities - EUROIMMUN [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term Debt, Percentage Bearing Fixed Interest, Amount | €

€ 45.3

Other Debt Facilities - EUROIMMUN [Member] | Euro Member Countries, Euro

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Other Long-term Debt | €

€ 39.8

€ 47.6

Vanadis Diagnostics AB [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Payments to Acquire Businesses, Net of Cash Acquired

$ 32,000

Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value

72,416

56,878

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

$ 93,000

Shanghai Spectrum Instruments Co., Ltd. [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value

$ 1,678

Minimum [Member] | Vanadis Diagnostics AB [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Projected milestone date

2,018

Conditional probability of success

90.00%

90.00%

Cumulative probability of success

73.00%

73.00%

Minimum [Member] | Vanadis Diagnostics AB [Member] | Measurement Input, Discount Rate [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Measurement Inputs, Discount Rate

3.10%

Maximum [Member] | Vanadis Diagnostics AB [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Projected milestone date

2,019

Conditional probability of success

100.00%

100.00%

Cumulative probability of success

100.00%

100.00%

Maximum [Member] | Vanadis Diagnostics AB [Member] | Measurement Input, Discount Rate [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Measurement Inputs, Discount Rate

9.10%

Significant Other Observable Inputs (Level 2) [Member] | 2021 Notes [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term Debt

$ 496,900

496,600

Significant Other Observable Inputs (Level 2) [Member] | Line of Credit, Maturing August 11, 2021 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term Debt

497,100

621,700

Significant Other Observable Inputs (Level 2) [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term Debt

575,100

591,700

Significant Other Observable Inputs (Level 2) [Member] | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Long-term Debt

347,200

Significant Other Observable Inputs (Level 2) [Member] | Financing Lease Obligations [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Other Long-term Debt

$ 35,300

$ 35,900

Significant Other Observable Inputs (Level 2) [Member] | Other Debt Facilities - EUROIMMUN [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Other Long-term Debt | €

€ 48.9

€ 60.2

Fair Value Measurements (Assets

Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) - USD ($) $ in Thousands	Jul. 01, 2018	Apr. 01, 2018	Dec. 31, 2017	Jul. 02, 2017	Apr. 02, 2017	Jan. 01, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 74,093	$ 65,445	$ 65,328	$ 64,076	$ 63,978	$ 63,201
Fair Value, Measurements, Recurring [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	2,271		2,208
Foreign exchange derivative assets, net	(3,367)		(1,431)
Foreign exchange derivative liabilities, net	(535)		(23,638)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	74,093		65,328
Fair Value, Measurements, Recurring [Member] | Quoted Prices In Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	2,271		2,208
Foreign exchange derivative assets, net	0		0
Foreign exchange derivative liabilities, net	0		0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	0		0
Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0		0
Foreign exchange derivative assets, net	(3,367)		(1,431)
Foreign exchange derivative liabilities, net	(535)		(23,638)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	0		0
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0		0
Foreign exchange derivative assets, net	0		0
Foreign exchange derivative liabilities, net	0		0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 74,093		$ 65,328

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Fair Value Disclosures [Abstract]
Balance beginning of period	$ (65,445,000)	$ (63,978,000)	$ (65,328,000)	$ (63,201,000)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases	(1,700,000)	0	(1,700,000)	0
Payments	0	0	0	34,000
Change in fair value (included within selling, general and administrative expenses)	(6,948,000)	(98,000)	(7,065,000)	(909,000)
Balance end of period	$ (74,093,000)	$ (64,076,000)	$ (74,093,000)	$ (64,076,000)

Contingencies (Details)

Contingencies (Details) $ in Millions	6 Months Ended
	Jul. 01, 2018USD ($)years	Dec. 31, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
Management's estimate of total cost of ultimate disposition | $	$ 9.1	$ 9.4
Number of years over which estimated environmental cost will be paid | years	10